

CITATION REPORT

List of articles citing

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

DOI: 10.1038/mt.2010.24

Molecular Therapy, 2010, 18, 843-51.

Source: <https://exaly.com/paper-pdf/49269921/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1897	Histoire et anthropologie sensorielle. 1990 , 14, 13-24		33
1896	Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). 2017 , 6, 159-168		24
1895	Adoptive cell therapy: genetic modification to redirect effector cell specificity. 2010 , 16, 336-41		74
1894	Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. 2010 , 116, 1035-44		237
1893	Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells. 2010 , 58, 165-78		10
1892	Designer lymphocytes to fight cancer: a helping hand from modern molecular biology. 2010 , 88, 1081-4		1
1891	T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. 2010 , 359, 11-20		10
1890	Carving the CAR. 2010 , 17, 1191-2		4
1889	Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. 2010 , 70, 9053-61		334
1888	Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. 2010 , 16, 3594-606		103
1887	Focus on adoptive T cell transfer trials in melanoma. 2010 , 2010, 260267		27
1886	Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirectioned T cells has caused serious adverse events. 2010 , 21, 1039-42		23
1885	Can engineered "designer" T cells outsmart chronic hepatitis B?. 2010 , 2010, 901216		3
1884	Tumor ablation by gene-modified T cells in the absence of autoimmunity. 2010 , 70, 9591-8		46
1883	Safer CARs. <i>Molecular Therapy</i> , 2010 , 18, 661-2	11.7	65
1882	Is it safer CARs that we need, or safer rules of the road?. <i>Molecular Therapy</i> , 2010 , 18, 1742-3	11.7	7
1881	Cell-based therapies: careful safety assessment for minimization of risk. 2010 , 12, 710-2		1

1880	Pluripotent stem cell-derived natural killer cells for cancer therapy. 2010 , 156, 147-54	46
1879	Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies. 2010 , 8, 55	8
1878	NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. 2010 , 16, 1037-69	36
1877	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 2010 , 16, 1467-503	107
1876	Adoptive cellular therapy. 2011 , 344, 149-72	18
1875	Development of adoptive cell therapy for cancer: a clinical perspective. 2010 , 21, 665-72	54
1874	Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. 2010 , 12, 743-9	64
1873	Thunder and lightning: immunotherapy and oncolytic viruses collide. <i>Molecular Therapy</i> , 2011 , 19, 1008-16.7	179
1872	Immunotherapy for metastatic solid cancers. 2011 , 45, 341-60	63
1871	Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. 2011 , 11, 855-73	111
1870	Experimental and Applied Immunotherapy. 2011 ,	
1869	Eliminating cells gone astray. 2011 , 365, 1735-7	11
1868	Defining the critical hurdles in cancer immunotherapy. 2011 , 9, 214	120
1867	Cancer Immunology and Immunotherapy. 2011 ,	1
1866	Transiently redirected T cells for adoptive transfer. 2011 , 13, 629-40	48
1865	Genetic modification of T cells. 2011 , 17, S15-20	29
1864	Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. 2011 , 365, 725-33	2502
1863	Cancer immunotherapy--revisited. 2011 , 10, 591-600	282

1862	Distribution of adoptively transferred porcine T-lymphoblasts tracked by (18)F-2-fluoro-2-deoxy-D-glucose and position emission tomography. 2011 , 38, 827-33	8
1861	Redirecting T cells. 2011 , 365, 754-7	24
1860	Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. 2011 , 8, 577-85	256
1859	Cellular therapy to treat haematological and other malignancies: progress and pitfalls. 2011 , 43, 605-15	3
1858	Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. 2011 , 2, 378-82	42
1857	In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. 2011 , 34, 469-79	16
1856	Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. 2011 , 17, 325-30	29
1855	The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. 2011 , 118, 946-54	34
1854	Autoimmunity associated with immunotherapy of cancer. 2011 , 118, 499-509	128
1853	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. 2011 , 118, 4817-28	950
1852	Engineered T cells for pancreatic cancer treatment. 2011 , 13, 643-50	44
1851	Treating cancer with genetically engineered T cells. 2011 , 29, 550-7	176
1850	Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions. 2011 , 30, 294-311	15
1849	Allogeneic and Autologous Transplantation Therapy of Cancer: Converging Themes. 2011 , 411-430	
1848	Current status and future applications of cellular therapies for cancer. 2011 , 3, 507-16	23
1847	Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. 2011 , 31, 710-8	82
1846	GUCY2C-targeted cancer immunotherapy: past, present and future. 2011 , 51, 161-9	8
1845	Biomarkers in T cell therapy clinical trials. 2011 , 9, 138	28

1844	New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future. 2011 , 37, 46		7
1843	Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. 2011 , 129, 2935-44		105
1842	Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. 2011 , 23, 299-305		31
1841	Adoptive immunotherapy of cancer: Gene transfer of T cell specificity. 2011 , 2, 80-84		9
1840	PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. <i>Molecular Therapy</i> , 2011 , 19, 2133-43	11.7	95
1839	CARs on track in the clinic. <i>Molecular Therapy</i> , 2011 , 19, 432-8	11.7	101
1838	Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. <i>Molecular Therapy</i> , 2011 , 19, 1928-30	11.7	9
1837	Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer. 2011 , 11, 699-713		6
1836	Treatment of advanced leukemia in mice with mRNA engineered T cells. 2011 , 22, 1575-86		149
1835	Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. 2011 , 71, 3175-81		56
1834	T-cell receptor gene therapy: critical parameters for clinical success. 2011 , 131, 1806-16		33
1833	Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. 2011 , 3, 33-48		39
1832	Inducible apoptosis as a safety switch for adoptive cell therapy. 2011 , 365, 1673-83		1031
1831	In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). 2011 , 71, 4617-27		210
1830	Ex vivo gene transfer for improved adoptive immunotherapy of cancer. 2011 , 20, R93-9		28
1829	Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. 2011 , 17, 4719-30		363
1828	Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. 2011 , 2011, 104926		11
1827	Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. 2012 , 2012, 278093		38

1826	TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. 2012 , 2012, 586314		34
1825	Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. 2012 , 2, 194		62
1824	Convergence of gene and cell therapy. 2012 , 7, 50-6		8
1823	Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. 2012 , 23, 376-86		82
1822	mRNA as a versatile tool for exogenous protein expression. 2012 , 12, 347-61		44
1821	Equipping CAR-modified T cells with a brake to prevent chronic adverse effects. 2012 , 12, 493-5		8
1820	Chasing cancer with chimeric antigen receptor therapy. 2012 , 4, 365-7		6
1819	Live and let die: a new suicide gene therapy moves to the clinic. <i>Molecular Therapy</i> , 2012 , 20, 11-3	11.7	24
1818	Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. <i>Molecular Therapy</i> , 2012 , 20, 948-53	11.7	184
1817	Gene-modified lymphocytes: from caution to promise for effective cancer immunotherapy. 2012 , 4, 241-4		
1816	IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA. 2012 , 4, 153-81		2
1815	A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). 2012 , 1, 863-873		62
1814	Model T muscle CARs can treat brain tumors. 2012 , 18, 5834-6		2
1813	Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. 2012 , 189, 1812-25		45
1812	Trial Watch: Adoptive cell transfer immunotherapy. 2012 , 1, 306-315		58
1811	A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. 2012 , 23, 70-82		24
1810	Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. 2012 , 97, 1622-31		12
1809	Therapeutic effect of ribbon-type nuclear factor- κ B decoy oligonucleotides in a rat model of inflammatory bowel disease. 2012 , 12, 484-92		15

1808	Adoptive cellular immunotherapy. 582-592	
1807	Gene transfer: methods and applications. 593-615	
1806	Good T cells for bad B cells. 2012 , 119, 2700-2	10
1805	CARs and cancers: questions and answers. 2012 , 119, 3872-3	11
1804	Will T-cell therapy for cancer ever be a standard of care?. 2012 , 19, 818-21	14
1803	T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation. 2012 , 5, 471-3	3
1802	Immunotherapy of breast cancer. 2012 , 12, 479-90	26
1801	Monoclonal antibody therapy for malignant glioma. 2012 , 746, 121-41	18
1800	Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells. 2012 , 488, 384-8	103
1799	Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. 2012 , 5, 409-25	15
1798	A dual role for genetically modified lymphocytes in cancer immunotherapy. 2012 , 18, 193-200	24
1797	CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. 2012 , 18, 377-84	149
1796	Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors. 2012 , 316, 1-5	18
1795	A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. 2012 , 10, 157	82
1794	Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. 2012 , 32, 1059-70	309
1793	Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. 2012 , 143, 1375-1384.e5	67
1792	Engineered T cells for anti-cancer therapy. 2012 , 24, 633-9	62
1791	Genetic modification of lymphocytes by retrovirus-based vectors. 2012 , 24, 598-608	34

1790 Adoptive Zelltherapien in der Hämatologie und Onkologie. **2012**, 18, 788-794

1789 Glioma. **2012**, 2

1788 Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). **2012**, 12, 615 47

1787 Antigen-receptor gene-modified T cells for treatment of glioma. **2012**, 746, 202-15 6

1786 Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. **2012**, 7, e49829 50

1785 Immunotherapy targets in pediatric cancer. **2012**, 2, 3 32

1784 Transposon-Based Engineering of Clinical-Grade T Cells for Cancer Therapy. **2012**, 7, 36-41

1783 Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. **2012**, 18, 565-76 82

1782 The past, present, and future of adoptive T cell therapy. **2012**, 12, 139-47 10

1781 Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. **2012**, 4, 520-31 2

1780 The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. **2012**, 18, 2780-90 98

1779 Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. **2012**, 61, 953-62 75

1778 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. **2012**, 119, 2709-20 1110

1777 Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. **2012**, 23, 444-50 86

1776 The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. **2012**, 9, 248-58 24

1775 Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. **2012**, 14, 405-15 171

1774 Lentiviral vector followed by protein immunisation breaks tolerance against the self-antigen Her1 and results in lung cancer immunotherapy. **2012**, 14, 151-7 5

1773 Challenges in T cell receptor gene therapy. **2012**, 14, 386-99 31

1772	Long-term follow-up of cancer patients treated with gene therapy medicinal products. 2012 , 14, 440-2	0
1771	Adoptive immunotherapy for cancer: harnessing the T cell response. 2012 , 12, 269-81	1192
1770	Genetic engineering of T cells for the immunotherapy of haematological malignancies. 2012 , 79, 4-14	6
1769	Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. 2012 , 167, 216-25	18
1768	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/ β null mice. 2012 , 103, 17-25	24
1767	Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. 2012 , 39, 215-26	26
1766	Genetically modulating T-cell function to target cancer. 2012 , 22, 14-22	35
1765	Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. 2012 , 61, 127-35	18
1764	Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. 2013 , 6, 47	63
1763	Mouse models in bone marrow transplantation and adoptive cellular therapy. 2013 , 50, 131-44	9
1762	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 2013 , 9, 977-90	19
1761	Gene-engineered T cells for cancer therapy. 2013 , 13, 525-41	340
1760	CARs in chronic lymphocytic leukemia -- ready to drive. 2013 , 8, 60-70	16
1759	Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. 2013 , 39, 49-60	360
1758	Double or nothing on cancer immunotherapy. 2013 , 31, 33-4	18
1757	Chimeric antigen receptor-redirectioned T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor. 2013 , 5, 577-90	5
1756	Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. 2013 , 62, 1563-73	44
1755	Do no harm. 2013 , 31, 365	5

1754	Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. 2013 , 15, 544-53	31
1753	Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. 2013 , 24, 717-27	84
1752	At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. 2013 , 94, 1141-57	44
1751	Chimeric antigen receptors (CARs) from bench-to-bedside. 2013 , 155, 40-2	16
1750	Reassessing target antigens for adoptive T-cell therapy. 2013 , 31, 999-1008	143
1749	The basic principles of chimeric antigen receptor design. 2013 , 3, 388-98	811
1748	Primer on tumor immunology and cancer immunotherapy. 2013 , 1, 12	49
1747	Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. 2013 , 11, 187	107
1746	Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRVIII chimeric antigen receptor in mice bearing human GBM xenografts. 2013 , 1, 21	61
1745	Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. <i>Molecular Therapy</i> , 2013 , 21, 904-12	11.7 460
1744	Advances in the development of cancer immunotherapies. 2013 , 34, 90-8	34
1743	Cancer immunotherapy: current status and future directions. 2013 , 22, 765-83	18
1742	Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. 2013 , 31, 71-5	586
1741	Genetically engineered T cells for the treatment of cancer. 2013 , 273, 166-81	33
1740	Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes. 2013 , 19, 320-6	11
1739	Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. 2013 , 161, 265-83	68
1738	The two sides of HER2/neu: immune escape versus surveillance. 2013 , 19, 677-84	15
1737	Synthetic mammalian gene circuits for biomedical applications. 2013 , 17, 910-7	33

1736	Innovation and opportunity for chimeric antigen receptor targeted T cells. 2013 , 15, 1046-53	7
1735	Automating the construction of gene ontologies. 2013 , 31, 34-5	9
1734	Cellular therapy of cancer with natural killer cells-where do we stand?. 2013 , 15, 1185-94	26
1733	The innovative evolution of cancer gene and cellular therapies. 2013 , 20, 141-9	14
1732	Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. 2013 , 161, 389-401	155
1731	T cells redirected to EphA2 for the immunotherapy of glioblastoma. <i>Molecular Therapy</i> , 2013 , 21, 629-37	11.7 171
1730	Clinical targeting of the TNF and TNFR superfamilies. 2013 , 12, 147-68	265
1729	Biomarkers in T-cell therapy clinical trials. 2013 , 15, 632-40	6
1728	Human cancer regression antigens. 2013 , 25, 284-90	29
1727	Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. 2013 , 9, 527-39	24
1726	Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. 2013 , 23, 516-26	109
1725	Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. 2013 , 20, 970-8	59
1724	Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. 2013 , 20, 1029-32	48
1723	T cell-based gene therapy of cancer. 2013 , 161, 365-79	16
1722	Improving the efficacy and safety of engineered T cell therapy for cancer. 2013 , 328, 191-7	34
1721	Better performance of CARs deprived of the PD-1 brake. 2013 , 19, 5546-8	11
1720	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 2013 , 24, 1740-1748	63
1719	Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. <i>Molecular Therapy</i> , 2013 , 21, 2122-9	11.7 299

1718	Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. 2013 , 1, 43-53	228
1717	Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. 2013 , 13, 65-70	12
1716	Challenges of creating effective chimeric antigen receptors for cancer therapy. 2013 , 5, 783-5	3
1715	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. 2013 , 7, 23-35	7
1714	Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. 2013 , 3, 197	29
1713	Adoptive cell therapies for glioblastoma. 2013 , 3, 275	38
1712	Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. 2013 , 2013, 371854	52
1711	Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. 2013 , 4, 371	90
1710	Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. 2013 , 19, 3153-64	330
1709	Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. 2013 , 36, 133-51	758
1708	Zoom Zoom: racing CARs for multiple myeloma. 2013 , 19, 1917-9	25
1707	PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. 2013 , 5, 215ra172	435
1706	Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. 2013 , 24, 134-42	88
1705	B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. 2013 , 19, 2048-60	385
1704	Monoclonal T-cell receptor drugs pique pharma's interest. 2013 , 31, 950-1	2
1703	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. 2013 , 5, 169-81	121
1702	Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?. 2013 , 191, 4589-98	88
1701	Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. <i>Molecular Therapy</i> , 2013 , 21, 2087-101	11.7 240

1700	Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells. 2013 , 20, 861-7	10
1699	Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. 2013 , 20, 24-34	16
1698	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. 2013 , 19, 5636-46	485
1697	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. 2013 , 110, 270-5	95
1696	Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. 2013 , 5, 197ra103	441
1695	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. 2013 , 122, 863-71	750
1694	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. 2013 , 122, 3461-72	246
1693	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. 2013 , 20, 289-97	80
1692	Developments in the treatment of hemophilia B: focus on emerging gene therapy. 2013 , 6, 91-101	9
1691	Genetically modified T cells for the treatment of malignant disease. 2013 , 40, 388-402	19
1690	Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. 2013 , 8, e82742	132
1689	Gene Therapy for Melanoma: Progress and Perspectives. 2013 ,	1
1688	Clinical application of adoptive T cell therapy in solid tumors. 2014 , 20, 953-9	11
1687	EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. 2014 , 9, e94281	85
1686	PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. 2014 , 9, e109427	52
1685	Improving the safety of cell therapy products by suicide gene transfer. 2014 , 5, 254	129
1684	Colorectal cancer and immunity: what we know and perspectives. 2014 , 20, 3738-50	93
1683	Immunotherapy in gastric cancer. 2014 , 20, 1657-66	65

1682	Adoptive Immunotherapy for Acute Myeloid Leukemia: From Allogeneic Hematopoietic Cell Transplantation to CAR T Cells. 2014 , 02,		
1681	T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. 2014 , 28, 468-75		38
1680	Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. 2014 , 3, e944059		7
1679	Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. 2014 , 13, 219		28
1678	Adoptive T-cell therapy: adverse events and safety switches. 2014 , 3, e17		58
1677	Current advances in T-cell-based cancer immunotherapy. 2014 , 6, 1265-78		92
1676	Reversal of tumor immune inhibition using a chimeric cytokine receptor. <i>Molecular Therapy</i> , 2014 , 22, 1211-1220	11.7	121
1675	Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. <i>Molecular Therapy</i> , 2014 , 22, 1029-38	11.7	29
1674	HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations. 2014 , 4, 791-823		
1673	HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium. 2014 , 4, 649-671		5
1672	HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. 2014 , 74, 5173-83		26
1671	Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. <i>Molecular Therapy</i> , 2014 , 22, 1134-1138	11.7	25
1670	Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers. 2014 , 13, 1447-62		11
1669	The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. 2014 , 5, 235		205
1668	Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. 2014 , 20, 6418-28		177
1667	Dendritic cell vaccine treatment of advanced colorectal cancer in renal transplant patients. 2014 , 51, 338-341		
1666	Cell transfer therapy for cancer: past, present, and future. 2014 , 2014, 525913		23
1665	Cancer immunotherapy: targeting the difference. 2014 , 61, 1175-7		3

1664	Characterizing the human hematopoietic CDome. 2014 , 5, 331	7
1663	Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial". 2014 , 16, 169-70	1
1662	T-Bodies: Antibody-Based Engineered T-Cell Receptors. 2014 , 83-129	
1661	Clinical Trial Design. 2014 , 179-201	
1660	Targeting CD8+ T-cell tolerance for cancer immunotherapy. 2014 , 6, 833-52	37
1659	Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses. 2014 , 33, 402-16	10
1658	Immunotherapy in pediatric malignancies: current status and future perspectives. 2014 , 10, 1659-78	10
1657	Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. 2014 , 10, 1779-94	7
1656	Advances in Tumor Immunology and Immunotherapy. 2014 ,	0
1655	CAR T cells: driving the road from the laboratory to the clinic. 2014 , 257, 91-106	77
1654	Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. 2014 , 257, 165-80	41
1653	Exploiting the curative potential of adoptive T-cell therapy for cancer. 2014 , 257, 56-71	338
1652	Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. 2014 , 257, 127-44	109
1651	Advances in T-cell therapy for ALL. 2014 , 27, 222-8	13
1650	A Systems Biology Approach to Blood. 2014 ,	2
1649	A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. 2014 , 124, 1277-87	199
1648	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. 2014 , 2, 25	82
1647	Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. 2014 , 37, 407-15	42

1646	CAR T cells for solid tumors: armed and ready to go?. 2014 , 20, 151-5	134
1645	Novel approaches to enhance the specificity and safety of engineered T cells. 2014 , 20, 160-5	31
1644	Harnessing the immune system for cancer therapy. 2014 , 26, 600-7	19
1643	Genetic modification of T cells. 2014 , 20, 145-50	12
1642	Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. 2014 , 6, 242ra83	278
1641	Genetically Engineered (T Cell Receptor) T Cells for Adoptive Therapy. 2014 , 259-271	0
1640	Current concepts in the diagnosis and management of cytokine release syndrome. 2014 , 124, 188-95	1520
1639	Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. 2014 , 7, 1049-68	17
1638	A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. 2014 , 2014, 326545	21
1637	Construction and evaluation of a novel humanized HER2-specific chimeric receptor. 2014 , 16, R61	73
1636	The emergence of T-bodies/CAR T cells. 2014 , 20, 123-6	37
1635	NKG2D CARs as cell therapy for cancer. 2014 , 20, 156-9	65
1634	CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. 2014 , 28, 917-27	292
1633	Engineered T cells for cancer treatment. 2014 , 16, 713-33	16
1632	Adoptive immunotherapy for cancer or viruses. 2014 , 32, 189-225	201
1631	Driving CAR-based T-cell therapy to success. 2014 , 9, 50-6	23
1630	Guest editorial: Immunotherapy for hematological malignancies: the quest to overcome tolerogenic drive. 2014 , 99, 105-6	
1629	Immunotherapy: opportunities, risks and future perspectives. 2014 , 16, S120-9	6

1628	Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. 2014 , 32, 798-808	341
1627	Nature Biotechnology's academic spinouts of 2013. 2014 , 32, 229-38	9
1626	Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. 2014 , 74, 3390-5	2
1625	Cancer Immunotherapy Meets Oncology. 2014 ,	
1624	Finding suitable targets is the major obstacle to cancer gene therapy. 2014 , 21, 45-7	25
1623	Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. 2014 , 343, 172-8	104
1622	Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?. 2014 , 150, 51-63	44
1621	Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. 2014 , 99, 123-31	12
1620	HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. 2014 , 63, 101-9	28
1619	Impact of T cell selection methods in the success of clinical adoptive immunotherapy. 2014 , 71, 1211-24	5
1618	Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. 2014 , 63, 133-45	18
1617	Mitigating the toxic effects of anticancer immunotherapy. 2014 , 11, 91-9	150
1616	T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. 2014 , 20, 962-71	58
1615	CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. 2014 , 14, 37-49	17
1614	Chimeric antigen receptor T-cell therapy to target hematologic malignancies. 2014 , 74, 6383-9	34
1613	A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. 2014 , 63, 1163-76	27
1612	Are natural killer cells superior CAR drivers?. 2014 , 3, e28147	150
1611	From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. 2014 , 41, 661-6	22

1610	Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. 2014 , 155, 160-75	113
1609	EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. 2014 , 20, 972-84	205
1608	Mechanism of action of immunotherapy. 2014 , 41 Suppl 5, S3-13	89
1607	Cancer immunotherapy: hype or ripe? [corrected]. 2014 , 44, 318-20	2
1606	Design and development of therapies using chimeric antigen receptor-expressing T cells. 2014 , 257, 107-26	338
1605	Epidermal growth factor receptor and variant III targeted immunotherapy. 2014 , 16 Suppl 8, viii20-5	22
1604	Immunotherapy advances for glioblastoma. 2014 , 16, 1441-58	136
1603	CARTs on the road for myeloma. 2014 , 20, 3899-901	13
1602	A closer look at chimeric antigen receptor specificity. 2014 , 16, 1323-4	2
1601	Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. 2014 , 2, 1059-70	52
1600	Chimeric Antigen Receptors [CARs] 2014 , 519-560	
1599	Adoptive T-cell therapy for Leukemia. 2014 , 2, 25	13
1598	Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. 2014 , 20, 2457-65	162
1597	Ethics in Translational Gene Transfer Research. 2014 , 517-526	1
1596	Engineered T cells for cancer therapy. 2014 , 63, 969-75	90
1595	A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. 2014 , 63, 999-1008	34
1594	Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer. 2014 , 41, 6317-23	3
1593	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. 2014 , 123, 2343-54	309

1592	Adoptive immunotherapy for cancer. 2014 , 257, 14-38	100
1591	Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. 2014 , 14, 1259-70	17
1590	A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. 2014 , 25, 1003-12	113
1589	Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. 2014 , 14, 947-54	18
1588	Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. <i>Molecular Therapy</i> , 2014 , 22, 623-633	11.7 83
1587	T-cell immunotherapy: looking forward. <i>Molecular Therapy</i> , 2014 , 22, 1564-74	11.7 51
1586	T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. 2014 , 1840, 378-86	47
1585	Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. 2014 , 21, 189-90	85
1584	Can calcium signaling be harnessed for cancer immunotherapy?. 2014 , 1843, 2334-40	6
1583	Gene and cell therapy for children--new medicines, new challenges?. 2014 , 73, 162-9	24
1582	Current Advances in Osteosarcoma. 2014 ,	7
1581	IL-2: the first effective immunotherapy for human cancer. 2014 , 192, 5451-8	660
1580	Synthetic therapeutic gene circuits in mammalian cells. 2014 , 588, 2537-44	52
1579	Clinical application of genetically modified T cells in cancer therapy. 2014 , 3, e16	83
1578	T cells redirected to interleukin-13R α 2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13R α 1. 2014 , 16, 1121-31	54
1577	Designer-T-Zellen: Können T-Zellen mit definierter Spezifität die adoptive Immuntherapie zum Erfolg führen?. 2014 , 4, 179-183	
1576	Engineered T cell therapies. 2015 , 17, e19	5
1575	CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia. 2015 , 82, 307-19	24

1574 Principles of Targeted Immunotherapy. **2015**, 27-38

1573 Chimeric Antigen Receptors for Cancer: Progress and Challenges. **2015**, 1, 187-196

1572 [Pluripotent stem cells as a source for T cell research and clinical application]. **2015**, 38, 101-8

1571 Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. **2015**, 6, 471-99 51

1570 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. **2015**, 62, 1326-36 9

1569 Smart CARs engineered for cancer immunotherapy. **2015**, 27, 466-74 46

1568 Paving the road ahead for CD19 CAR T-cell therapy. **2015**, 22, 516-20 15

1567 Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity. **2015**, 21, 475-9 10

1566 Research Highlights. **2015**, 99, 2434-2435 1

1565 T Cell Redirecting Therapies for Cancer Treatment. **2016**, 16, 22-33 2

1564 Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. **2015**, 6, 44179-90 69

1563 Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity. **2015**, 4, 426-440 20

1562 Seatbelts in CAR therapy: How Safe Are CARs?. **2015**, 8, 230-49 40

1561 Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. **2015**, 6, 605 123

1560 Immunotherapy of Childhood Sarcomas. **2015**, 5, 181 44

1559 Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. **2015**, 3, 80 15

1558 Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. **2015**, 6, 171-84 94

1557 A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. **2015**, 9, 4989-96 43

1556	In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer. 2015 , 2015, 482089	15
1555	Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy. 2015 , 2015, 675269	13
1554	Human Tumor Antigens and Cancer Immunotherapy. 2015 , 2015, 948501	130
1553	A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. 2015 , 6, 21533-46	58
1552	Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. 2015 , 7, 275ra22	301
1551	Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. 2015 , 26, 276-85	11
1550	TRUCKs: the fourth generation of CARs. 2015 , 15, 1145-54	297
1549	Drug development: Mix and match. 2015 , 521, S12-4	6
1548	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. 2015 , 4, e994374	29
1547	Preclinical safety testing for cell-based products using animals. 2015 , 43, 425-8	3
1546	Immunology and Immunotherapy of Breast Cancer. 2015 , 457-470	
1545	T-Cell Costimulation and Its Applications in Diseases. 2015 , 255-292	3
1544	T-Cell Immunotherapy for Cancer. 2015 , 389-410	
1543	Immunotherapy for malignant glioma. 2015 , 6, S68-77	31
1542	T Cell Engineering. 2015 , 42, 110-35	3
1541	Developments in T Cell Based Cancer Immunotherapies. 2015 ,	
1540	T-cell receptor gene therapy--ready to go viral?. 2015 , 9, 2019-42	20
1539	Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. 2015 , 3, 55	48

1538 Chimeric Antigen Receptor (CAR) T Cells. **2015**, 259-280

1537 CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies. **2015**, 38, 683-90 14

1536 Adoptive immunotherapy against sarcomas. **2015**, 15, 517-28 9

1535 Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer. **2015**, 230, 1457-65 13

1534 Overcoming the toxicity hurdles of genetically targeted T cells. **2015**, 64, 123-30 44

1533 Target antigen density governs the efficacy of anti-CD20-CD28-CD3 [chimeric antigen receptor-modified effector CD8+ T cells. **2015**, 194, 911-20 150

1532 Targeting the tumor vasculature to enhance T cell activity. **2015**, 33, 55-63 169

1531 Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. **2015**, 15, 403-16 3

1530 Designing chimeric antigen receptors to effectively and safely target tumors. **2015**, 33, 9-15 117

1529 DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. **2015**, 64, 409-18 20

1528 Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. **2015**, 3, 206-16 112

1527 Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. **2015**, 67, 46-57 81

1526 ImmTACs for targeted cancer therapy: Why, what, how, and which. **2015**, 67, 67-74 59

1525 Are all chimeric antigen receptors created equal?. **2015**, 33, 651-3 19

1524 The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation. **2015**, 64, 551-62 14

1523 Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. **2015**, 16, 1 101

1522 T Cell-Based Gene Therapy of Cancer. **2015**, 281-304

1521 Risks of Insertional Mutagenesis by DNA Transposons in Cancer Gene Therapy. **2015**, 65-83 3

1520	CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. 2015 , 7, 545-61	21
1519	Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. 2015 , 7, 535-44	43
1518	Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. 2015 , 42, 626-39	64
1517	The Evolution of T-cell Therapies for Solid Malignancies. 2015 , 21, 3384-92	65
1516	Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. 2015 , 11, 125-140	21
1515	Reply to: "To target or not to target viral antigens in HBV related HCC?". 2015 , 62, 1450-2	3
1514	[New immunotherapeutic approaches in oncology and hematology]. 2015 , 22, 132-40	1
1513	Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer. 2015 , 3, 1130-7	25
1512	Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma. 2015 , 8, 383-5	5
1511	Adoptive T-cell therapy: a need for standard immune monitoring. 2015 , 7, 513-33	16
1510	Advantages and applications of CAR-expressing natural killer cells. 2015 , 6, 21	164
1509	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. 2015 , 135-183	
1508	CAR T-cell therapy: toxicity and the relevance of preclinical models. 2015 , 7, 487-97	65
1507	Engineering CAR-T cells: Design concepts. 2015 , 36, 494-502	247
1506	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. 2015 , 5, 11483	189
1505	Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. 2015 , 195, 755-61	124
1504	Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. 2015 , 19, 1339-50	16
1503	CCR 20th Anniversary Commentary: Chimeric Antigen Receptors-From Model T to the Tesla. 2015 , 21, 3099-101	

1502	Gene Therapy of Solid Cancers. 2015 ,	1
1501	The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. 2015 , 128, 1-68	34
1500	Synthetic biology in cell-based cancer immunotherapy. 2015 , 33, 449-61	52
1499	The pharmacology of second-generation chimeric antigen receptors. 2015 , 14, 499-509	293
1498	Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. 2015 , 34, 154-87	50
1497	ErbB-targeted CAR T-cell immunotherapy of cancer. 2015 , 7, 229-41	20
1496	Toxicities of Immunotherapy for the Practitioner. 2015 , 33, 2092-9	430
1495	Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. 2015 , 29, 75-89	43
1494	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. 2015 , 15, 857-72	15
1493	Adoptive cell transfer as personalized immunotherapy for human cancer. 2015 , 348, 62-8	1420
1492	AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells. 2015 , 8, 18	21
1491	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. 2015 , 240, 1087-98	37
1490	Intracellular caspase-modulating chimeric antigen receptor. 2015 , 20, 629-34	
1489	Genetically modified T cells in cancer therapy: opportunities and challenges. 2015 , 8, 337-50	109
1488	To target or not to target viral antigens in HBV related HCC?. 2015 , 62, 1449-50	4
1487	Inducible caspase-9 suicide gene controls adverse effects from alloplete T cells after haploidentical stem cell transplantation. 2015 , 125, 4103-13	149
1486	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. 2015 , 33, 1688-96	607
1485	Immune Therapy in GI Malignancies: A Review. 2015 , 33, 1745-53	29

1484	Synthetic immunity to break down the bottleneck of cancer immunotherapy. 2015 , 60, 977-985		2
1483	Chimeric antigen receptor T cells for cancer immunotherapy. 2015 , 33, 1703-6		49
1482	Redirection of genetically engineered CAR-T cells using bifunctional small molecules. 2015 , 137, 2832-5		105
1481	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. 2015 , 21, 2993-3002		42
1480	B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. 2015 , 22, 675-84		42
1479	Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL. 2015 , 125, 2958-67		7
1478	Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. 2015 , 350, aab4077		416
1477	T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. 2015 , 3, 1115-22		121
1476	Immune checkpoints and immunotherapy for colorectal cancer. 2015 , 3, 289-97		61
1475	Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. 2015 , 64, 1623-35		27
1474	Antitumor enhancement by irradiated haploidentical donor lymphocyte infusion of mice with melanoma. 2015 , 35, 2181-91		8
1473	Immunological landscape and immunotherapy of hepatocellular carcinoma. 2015 , 12, 681-700		344
1472	Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy. <i>Molecular Therapy</i> , 2015 , 23, 1559-61	11.7	11
1471	Designing CAR T cells for glioblastoma. 2015 , 4, e1048956		16
1470	The Dynamics of Interactions Among Immune and Glioblastoma Cells. 2015 , 17, 335-52		21
1469	Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras. 2015 , 4, e1047582		44
1468	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. <i>Molecular Therapy</i> , 2015 , 23, 1541-50	11.7	76
1467	Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. 2015 , 7, 999-1010		21

1466	Adoptive cell therapy for sarcoma. 2015 , 7, 21-35		9
1465	Are BiTEs the "missing link" in cancer therapy?. 2015 , 4, e1008339		49
1464	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. 2015 , 75, 3596-607		298
1463	Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors. 2015 , 1317, 365-82		26
1462	Landscape of Tumor Antigens in T Cell Immunotherapy. 2015 , 195, 5117-22		100
1461	CAR T-cell immunotherapy: The path from the by-road to the freeway?. 2015 , 9, 1994-2018		34
1460	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. 2015 , 385, 517-528		1926
1459	Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. 2015 , 263, 68-89		237
1458	Synthetic immunology: modulating the human immune system. 2015 , 33, 65-79		34
1457	Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. <i>Molecular Therapy</i> , 2015 , 23, 330-8	11.7	187
1456	Will post-transplantation cell therapies for pediatric patients become standard of care?. 2015 , 21, 402-11		8
1455	Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy. 2016 , 36, 329-347		7
1454	Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update. 2016 , 7,		2
1453	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. 2016 , 2016, 3850839		25
1452	CAR T Cell Therapy: A Game Changer in Cancer Treatment. 2016 , 2016, 5474602		86
1451	Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. 2016 , 11, e0159477		41
1450	New Strategies for the Treatment of Solid Tumors with CAR-T Cells. 2016 , 12, 718-29		47
1449	The emerging role of immunotherapy in colorectal cancer. 2016 , 4, 305		49

1448	Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19. 2016 , 7, 105	54
1447	Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. 2016 , 7, 176	19
1446	Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. 2016 , 7, 345	50
1445	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. 2016 , 6, 256	28
1444	Genetic Modification of T Cells. 2016 , 4,	22
1443	Synergistic effect of chimeric antigen receptors and cytokine-induced killer cells: An innovative combination for cancer therapy. 2016 , 3,	1
1442	An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. 2016 , 11, e0152196	36
1441	Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. 2016 , 7, 23282-99	48
1440	The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. 2016 , 173, 350-64	16
1439	A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells. 2016 , 39, 105-16	13
1438	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. 2016 , 101, 616-25	100
1437	The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies. 2016 , 22, 27-33	8
1436	Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. 2016 , 128, 7646-7650	5
1435	Chimeric antigen receptors: driving immunology towards synthetic biology. 2016 , 41, 68-76	54
1434	Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. 2016 , 63, 1780-5	73
1433	Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. 2016 , 76, 1257-70	147
1432	Prospects for chimeric antigen receptor (CAR) T cells: A potential game changer for adoptive T cell cancer immunotherapy. 2016 , 380, 413-423	81
1431	Plasma IFN- γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells. 2016 , 169, 107-113	8

1430	Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. 2016 , 166, 30-9	81
1429	Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. 2016 , 3, 16024	12
1428	Canine cancer immunotherapy studies: linking mouse and human. 2016 , 4, 97	62
1427	Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors. 2016 , 3, 16026	22
1426	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. 2016 , 8, 1393-1404	7
1425	Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. 2016 , 1, 16002	77
1424	Chimeric antigen receptor-modified T cells strike back. 2016 , 28, 355-63	17
1423	Redirecting T Cell Specificity Using T Cell Receptor Messenger RNA Electroporation. 2016 , 1428, 285-96	3
1422	Synthetic mRNA. 2016 ,	0
1421	The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. 2016 , 31-65	
1420	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. 2016 , 9, 1091-108	8
1419	Synthetic biology approaches in cancer immunotherapy, genetic network engineering, and genome editing. 2016 , 8, 504-17	6
1418	Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. 2016 , 22, 1875-84	182
1417	Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. 2016 , 13, 999-1013	6
1416	A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice. 2016 , 22, 4133-44	13
1415	Strategies to genetically engineer T cells for cancer immunotherapy. 2016 , 65, 631-49	38
1414	Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. 2016 , 127, 722-34	28
1413	Toxicities of chimeric antigen receptor T cells: recognition and management. 2016 , 127, 3321-30	727

1412	Review on the immunotherapy strategies against metastatic colorectal carcinoma. 2016 , 8, 1245-61	6
1411	Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. 2016 , 18, 1393-1409	67
1410	Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy. 2016 , 127-161	
1409	The growing world of CAR T cell trials: a systematic review. 2016 , 65, 1433-1450	83
1408	Development of chimeric antigen receptors for multiple myeloma. 2016 , 44, 397-405	4
1407	Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. 2016 , 44, 951-9	82
1406	Advances in PET Detection of the Antitumor T Cell Response. 2016 , 131, 187-231	32
1405	Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. 2016 , 167, 419-432.e16	335
1404	Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation. 2016 , 27, 758-771	29
1403	Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells. 2016 , 197, 1597-608	12
1402	Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy. 2016 , 8, 983-6	
1401	Socializing Individualized T-Cell Cancer Immunotherapy. <i>Molecular Therapy</i> , 2016 , 24, 1170-3	11.7 1
1400	Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model. 2016 , 40, 204-13	4
1399	The immune system and cancer evasion strategies: therapeutic concepts. 2016 , 279, 541-62	146
1398	Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. 2016 , 6, e458	130
1397	Employing dynamical computational models for personalizing cancer immunotherapy. 2016 , 16, 1373-1385	19
1396	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. 2016 ,	1
1395	Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. 2016 , 80, 8718-8724	56

1394	Engineered T cells: the promise and challenges of cancer immunotherapy. 2016 , 16, 566-81		662
1393	Tools and applications in synthetic biology. 2016 , 105, 20-34		35
1392	Improving the safety of T-Cell therapies using an inducible caspase-9 gene. 2016 , 44, 1013-1019		38
1391	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. 2016 , 8, 360-74		33
1390	Dynamic imaging for CAR-T-cell therapy. 2016 , 44, 386-90		11
1389	Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?. 2016 , 44, 406-11		14
1388	From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. 2016 , 16, 1469-1478		11
1387	GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. 2016 , 5, e1227897		40
1386	The integrin $\alpha 8$: a novel target for CAR T-cell immunotherapy?. 2016 , 44, 349-55		16
1385	Modular engineering of cellular signaling proteins and networks. 2016 , 39, 106-114		46
1384	Cellular immunotherapy for malignant gliomas. 2016 , 16, 1265-75		30
1383	Peptide vaccination therapy: Towards the next generation. 2016 , 66, 547-553		15
1382	Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. <i>Molecular Therapy</i> , 2016 , 24, 1602-14	11.7	70
1381	Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy. <i>Molecular Therapy</i> , 2016 , 24, 1987-1999	11.7	23
1380	Redirecting immunity covalently incorporated immunogenic sialic acid on the tumor cell surface. 2016 , 7, 3737-3741		12
1379	At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies. 2016 , 100, 1265-1272		27
1378	In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy. 2016 , 17, 286		11
1377	Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. 2016 , 45, 947-948		20

1376	Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. 2016 , 197, 4674-4685	38
1375	Design of chimeric antigen receptors with integrated controllable transient functions. 2016 , 6, 18950	60
1374	CAR models: next-generation CAR modifications for enhanced T-cell function. 2016 , 3, 16014	93
1373	Chimeric antigen receptor T cell therapy in AML: How close are we?. 2016 , 29, 329-333	20
1372	Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies. 2016 , 34, 566-576	5
1371	Toxicity and management in CAR T-cell therapy. 2016 , 3, 16011	512
1370	Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. 2016 , 5, e1211218	26
1369	CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside. 2016 , 5, e1251539	38
1368	Clinical development of gene therapy: results and lessons from recent successes. 2016 , 3, 16034	146
1367	Immunotherapy in Gastrointestinal Malignancies. 2016 , 27-69	
1366	Avidity characterization of genetically engineered T-cells with novel and established approaches. 2016 , 17, 23	13
1365	Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. 2016 , 55, 7520-4	65
1364	Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. 2016 , 39, 191-201	22
1363	Biology and clinical application of CAR T cells for B cell malignancies. 2016 , 104, 6-17	47
1362	TriKEs and BiKEs join CARs on the cancer immunotherapy highway. 2016 , 12, 2790-2796	34
1361	Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. 2016 , 44, 1444-54	338
1360	Immunopharmacology. 2016 ,	3
1359	A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. 2016 , 4, 658-68	88

1358	The best of both worlds: reaping the benefits from mammalian and bacterial therapeutic circuits. 2016 , 34, 11-19	10
1357	Personalized immunotherapy in colorectal cancer. 2016 , 1, 267-277	2
1356	Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. 2016 , 164, 770-9	529
1355	Strategies and developments of immunotherapies in osteosarcoma. 2016 , 11, 511-520	38
1354	Chimeric antigen receptor T cell treatment in hematologic malignancies. 2016 , 54, 35-40	3
1353	CD123 redirected multiple virus-specific T cells for acute myeloid leukemia. 2016 , 41, 76-84	10
1352	Chimeric antigen receptor-redirectioned T cells return to the bench. 2016 , 28, 3-9	22
1351	Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. 2016 , 5, e1122158	16
1350	Versatile strategy for controlling the specificity and activity of engineered T cells. 2016 , 113, E450-8	167
1349	Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. 2016 , 113, E459-68	240
1348	Novel targets for natural killer/T-cell lymphoma immunotherapy. 2016 , 8, 45-55	5
1347	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. 2016 , 76, 1578-90	308
1346	Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. 2016 , 22, 4380-90	101
1345	Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. 2016 , 21, 769-85	10
1344	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. 2016 , 59, 468-79	160
1343	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. 2016 , 141, 86-94	21
1342	Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. 2016 , 5, e1138199	2
1341	Adoptive therapy with CAR redirected T cells for hematological malignancies. 2016 , 59, 370-8	7

1340	Driving CAR T-cells forward. 2016 , 13, 370-83	362
1339	Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. <i>Molecular Therapy</i> , 2016 , 24, 736-45	11.7 7
1338	Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells. 2016 , 5, 395-404	46
1337	Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. 2016 , 108,	149
1336	Osteosarcoma. 2016 ,	1
1335	Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. 2016 , 59, 360-9	23
1334	High-affinity FRET-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. 2016 , 30, 1355-64	72
1333	Genetically Engineered T Cells. 2016 , 121-132	
1332	T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. 2016 , 5, e1040216	28
1331	Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. 2016 , 59, 386-97	94
1330	Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. 2016 , 59, 340-8	43
1329	Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. 2016 , 37, 220-230	138
1328	Prospects for gene-engineered T cell immunotherapy for solid cancers. 2016 , 22, 26-36	243
1327	Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. <i>Molecular Therapy</i> , 2016 , 24, 823-31	11.7 23
1326	Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. 2016 , 56, 59-83	87
1325	Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. 2016 , 1865, 90-100	17
1324	Chimeric antigen receptor T cell therapy: 25years in the making. 2016 , 30, 157-67	152
1323	Novel Treatments in Development for Melanoma. 2016 , 167, 371-416	10

1322	Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. 2016 , 6, 133-46		260
1321	Synthetic Biology--Toward Therapeutic Solutions. 2016 , 428, 945-62		24
1320	CAR-modified T-cell therapy for cancer: an updated review. 2016 , 44, 1339-49		36
1319	Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility. 2017 , 23, 466-477		54
1318	Masked Chimeric Antigen Receptor for Tumor-Specific Activation. <i>Molecular Therapy</i> , 2017 , 25, 274-284	11.7	49
1317	A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. 2017 , 10, 1		144
1316	Chimaeric antigen receptor T-cell therapy for tumour immunotherapy. 2017 , 37,		12
1315	Cell Based Therapy: Modified Cancer Cells. 2017 , 23-46		
1314	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. 2017 , 77, 1296-1309		46
1313	Targeting of Aberrant $\alpha 4 \beta 1$ Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. <i>Molecular Therapy</i> , 2017 , 25, 259-273	11.7	50
1312	Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. 2017 , 69, 1135-1143		177
1311	A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. 2017 , 6, e1287246		57
1310	The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. <i>Molecular Therapy</i> , 2017 , 25, 314-320	11.7	33
1309	New development in CAR-T cell therapy. 2017 , 10, 53		188
1308	Targeting neoantigens to augment antitumour immunity. 2017 , 17, 209-222		449
1307	T Cell-Associated Immunotherapy for Hepatocellular Carcinoma. 2017 , 41, 609-622		25
1306	CARs in the Lead Against Multiple Myeloma. 2017 , 12, 119-125		24
1305	Safety of Intra-Arterial Injection With Tumor-Activated T Cells to the Rabbit Brain Evaluated by MRI and SPECT/CT. 2017 , 26, 283-292		4

1304	An oxygen sensitive self-decision making engineered CAR T-cell. 2017 , 7, 39833		102
1303	Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. 2017 , 10, 549-557		18
1302	The Principles of Engineering Immune Cells to Treat Cancer. 2017 , 168, 724-740		583
1301	The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. 2017 , 45, 23-35		22
1300	The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. 2017 , 24, 89-99		18
1299	Immunologic approaches for the treatment of multiple myeloma. 2017 , 55, 190-199		25
1298	CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. 2017 , 23, 430-450		67
1297	Cell-Based Cancer Immunotherapy. 2017 , 1-10		
1296	HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. 2017 , 3, 1094-1101		378
1295	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. 2017 , 8, 573-589		47
1294	Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. 2017 , 399, 44-52		32
1293	Sensing Bad: Are Co-stimulatory CAR-Expressing Γ Cells Safer?. <i>Molecular Therapy</i> , 2017 , 25, 1064-1066	11.7	1
1292	CAR T-cell therapy: Balance of efficacy and safety. 2017 , 51, 237-250		4
1291	Surface engineering for lymphocyte programming. 2017 , 114, 102-115		13
1290	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. <i>Molecular Therapy</i> , 2017 , 25, 1946-1958	11.7	141
1289	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. 2017 , 66, 1113-1121		22
1288	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. 2017 , 17, 50		6
1287	Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. 2017 , 40, 104-107		40

1286	Modular lentiviral vector system for chimeric antigen receptor design optimization. 2017 , 43, 107-114		3
1285	CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. 2017 , 187, 1-10		57
1284	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. 2017 , 8, 896-925		40
1283	Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia. <i>Molecular Therapy</i> , 2017 , 25, 1933-1945	11.7	87
1282	Recent advances in T-cell immunotherapy for haematological malignancies. 2017 , 176, 688-704		18
1281	Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity. 2017 , 6, 1484-1495		19
1280	Adoptive T cell therapy: An overview of obstacles and opportunities. 2017 , 123, 2154-2162		59
1279	Combinatorial drug delivery approaches for immunomodulation. 2017 , 114, 161-174		29
1278	Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. 2017 , 187, 11-21		16
1277	Immunotherapy for Breast Cancer: What Are We Missing?. 2017 , 23, 2640-2646		112
1276	Practical considerations for chimeric antigen receptor design and delivery. 2017 , 17, 961-978		9
1275	Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. 2017 , 6, 10		53
1274	Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. <i>Molecular Therapy</i> , 2017 , 25, 1234-1247	11.7	48
1273	T-cell target antigens across major gynecologic cancers. 2017 , 145, 426-435		18
1272	CAR T-Cell Therapy: Progress and Prospects. 2017 , 28, 61-66		40
1271	Development of CAR T cells designed to improve antitumor efficacy and safety. 2017 , 178, 83-91		67
1270	Strategies for Increasing Pancreatic Tumor Immunogenicity. 2017 , 23, 1656-1669		92
1269	Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. 2017 , 39, 1010428317695949		13

1268	Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches. 2017 , 331, 289-383		37
1267	CAR T-cell therapy for pancreatic cancer. 2017 , 116, 63-74		47
1266	Modification of cytokine-induced killer cells with folate receptor alpha (FR α)-specific chimeric antigen receptors enhances their antitumor immunity toward FR α -positive ovarian cancers. 2017 , 85, 293-304		19
1265	Cancer Immunotherapy: Whence and Whither. 2017 , 15, 635-650		24
1264	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. 2017 , 31, 476-485		86
1263	Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers. <i>Molecular Therapy</i> , 2017 , 25, 1248-1258	11.7	188
1262	Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles. 2017 , 39, 1010428317692229		92
1261	Recognizing and managing on toxicities in cancer immunotherapy. 2017 , 39, 1010428317694542		22
1260	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. 2017 , 6, e1267891		48
1259	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. 2017 , 178, 31-47		58
1258	Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy. 2017 , 1, 447-466		21
1257	CAR T-cell therapy of solid tumors. 2017 , 95, 356-363		106
1256	Immuno-Oncology: The Third Paradigm in Early Drug Development. 2017 , 12, 125-138		16
1255	Driving gene-engineered T cell immunotherapy of cancer. 2017 , 27, 38-58		173
1254	Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. 2017 , 66, 475-489		53
1253	BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. 2017 , 129, 582-586		38
1252	Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins. 2017 , 1499, 165-178		18
1251	The Safety of available immunotherapy for the treatment of glioblastoma. 2017 , 16, 277-287		15

1250	Tumor-targeting domains for chimeric antigen receptor T cells. 2017 , 9, 33-46	5
1249	Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. 2017 , 12, 305-330	42
1248	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. 2017 , 23, 2478-2490	71
1247	Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. 2017 , 7, 14366	72
1246	Gene editing in T cell therapy. 2017 , 44, 415-422	13
1245	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. 2017 , 32, 506-519.e5	146
1244	Innovative Therapy, Monoclonal Antibodies and Beyond. 2017 , 38, 1-9	3
1243	CARs on a highway with roadblocks. 2017 , 6, e1388486	5
1242	Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy. 2017 , 171, 1138-1150.e15	81
1241	Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens. 2017 , 17, 1099-1106	15
1240	Mechanisms regulating T-cell infiltration and activity in solid tumors. 2017 , 28, xii18-xii32	175
1239	Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy. 2017 , 3, 726-741	16
1238	Novel Immunotherapies for Multiple Myeloma. 2017 , 12, 344-357	27
1237	RNA-transfection of $\gamma\delta$ T cells with a chimeric antigen receptor or an $\alpha\beta$ T-cell receptor: a safer alternative to genetically engineered $\alpha\beta$ T cells for the immunotherapy of melanoma. 2017 , 17, 551	55
1236	Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. 2017 , 109,	18
1235	Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells. 2017 , 28, 1047-1060	33
1234	Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. 2017 , 190, 201-205	6
1233	Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials. 2017 , 12, 623-636	8

1232	Adoptive cell therapy in multiple Myeloma. 2017 , 17, 1511-1522		9
1231	Adoptiver Immuntransfer und CAR-T-Zellen bei malignen Erkrankungen. 2017 , 23, 815-822		
1230	Chimeric antigen receptor T-cell therapies for multiple myeloma. 2017 , 130, 2594-2602		128
1229	Gene Modified T Cell Therapies for Hematological Malignancies. 2017 , 31, 913-926		2
1228	Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy. 2017 , 9, 851-861		7
1227	Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy. 2017 , 9, 837-849		1
1226	Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. 2017 , 130, 1985-1994		89
1225	Chimeric antigen receptor T-cell therapy for glioblastoma. 2017 , 187, 93-102		21
1224	Treating breast cancer with cell-based approaches: an overview. 2017 , 17, 1255-1264		4
1223	Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. <i>Molecular Therapy</i> , 2017 , 25, 2466-2476	11.7	41
1222	A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells. <i>Molecular Therapy</i> , 2017 , 25, 1997-1998	11.7	2
1221	Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Molecular Therapy</i> , 2017 , 25, 2245-2253	11.7	171
1220	Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. 2017 , 9, 1183-1197		271
1219	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. 2017 , 6, e1363139		37
1218	Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. 2017 , 30, 673-684		24
1217	CARTs for Solid Tumors: Feasible or Infeasible?. 2017 , 40, 540-546		2
1216	Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. 2017 , 7, 1306-1319		81
1215	NK-92 cell, another ideal carrier for chimeric antigen receptor. 2017 , 9, 753-765		12

1214	'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors. 2017 , 9, 723-733	11
1213	Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers. 2017 , 9, 1339-1349	7
1212	CAR T Cells for Solid Tumors. 2017 , 3, 269-278	
1211	Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. 2017 , 7, e017075	27
1210	Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors. 2017 , 3, e00438	7
1209	The activated conformation of integrin β s a novel multiple myeloma-specific target for CAR T cell therapy. 2017 , 23, 1436-1443	73
1208	Targeting EGFRvIII for glioblastoma multiforme. 2017 , 403, 224-230	34
1207	[Adoptive transfer of T lymphocytes]. 2017 , 24, 256-262	
1206	Chimeric antigen receptor T-cells for B-cell malignancies. 2017 , 187, 59-82	17
1205	A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells. <i>Molecular Therapy</i> , 2017 , 25, 2270-2279	11.7 3
1204	Engineering CAR-T cells. 2017 , 5, 22	199
1203	Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. 2017 , 5, 22	136
1202	Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities. 2017 , 9, 669-680	9
1201	Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. 2017 , 23, 5824-5835	41
1200	The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. 2017 , 66, 1425-1436	183
1199	'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes. 2017 , 47, 2-12	16
1198	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. 2017 , 23, 2491-2505	108
1197	Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. 2017 , 38, 15-24	52

1196	Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. 2017 , 23, 3061-3071	89
1195	CAR T Cell Therapy for Solid Tumors. 2017 , 68, 139-152	396
1194	Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. 2017 , 37, 129-143	21
1193	Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them. 2017 , 24, 121-129	18
1192	Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. 2017 , 23, 2267-2276	41
1191	Is Participation in Cancer Phase I Trials Really Therapeutic?. 2017 , 35, 135-138	35
1190	CAR T-cells for cancer therapy. 2017 , 33, 190-226	21
1189	T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases. 2017 , 51, 874-886	1
1188	New Approaches in CAR-T Cell Immunotherapy for Breast Cancer. 2017 , 1026, 371-381	20
1187	The Role of Tumor Microenvironment in Cancer Immunotherapy. 2017 , 1036, 51-64	64
1186	Cellulaire immunotherapie. 2017 , 34, 149	
1185	Development of tumor vessel-injuring CAR-T cell therapy for refractory solid cancer. 2017 , 32, 184-191	
1184	Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. 2017 , 40, 68-77	17
1183	CAR-T cell therapy in combination with allogeneic stem cell transplantation. 2017 , 6, 1-7	1
1182	Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. 2017 , 127, 2176-2191	171
1181	CARs on the Highway: Chimeric Antigen Receptor Modified T Cells for the Adoptive Cell Therapy of Malignant Diseases. 2017 ,	2
1180	Immunotherapy in Gastrointestinal Cancers. 2017 , 2017, 4346576	45
1179	The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells. 2017 , 8, 1690-1703	12

1178	Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease. 2017 , 5,	3
1177	Immune-Mediated Therapies for Liver Cancer. 2017 , 8,	17
1176	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. 2017 , 8, 267	47
1175	Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. 2017 , 8, 533	158
1174	Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment. 2017 , 8, 654	37
1173	The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors. 2017 , 8, 1640	6
1172	Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. 2017 , 8, 1655	16
1171	Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. 2017 , 8, 1850	111
1170	New Chimeric Antigen Receptor Design for Solid Tumors. 2017 , 8, 1934	17
1169	Chimeric Antigen Receptor Therapy of Brain Tumors. 2017 , 337-365	
1168	Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells. 2017 , 18,	13
1167	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. 2017 , 8, 90521-90531	62
1166	Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. 2017 , 10, 151	66
1165	Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. 2017 , 19, 76	36
1164	Prospects for combined use of oncolytic viruses and CAR T-cells. 2017 , 5, 90	67
1163	A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. 2017 , 8, 89256-89268	89
1162	Adoptive T-Cell Therapy for Solid Tumors. 2017 , 37, 193-204	39
1161	More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies?. 2017 , 4, 134	7

1160 Clinical Applications of Natural Killer Cells. **2017,**

1159 Viroimmunotherapy for Colorectal Cancer: Clinical Studies. **2017, 5,** 19

1158 Adoptive Cell Therapy for Cancer Using T-Cells Genetically Engineered to Express Chimeric Antigen Receptors. 591-601

1157 Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells. **2017, 12, 188-196** 8

1156 Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR". **2017, 8, 31368-31385** 59

1155 Adoptive T-Cell Therapy for Solid Tumors. **2017, 37, 193-204** 41

1154 CAR-T cell therapy in ovarian cancer: from the bench to the bedside. **2017, 8, 64607-64621** 30

1153 Novel Targeted Agents and Immunotherapy in Breast Cancer. **2017, 37, 65-75** 5

1152 Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. **2018, 90, 116-131** 32

1151 CAR-T Cells: Next Generation Cancer Therapeutics. **2018, 98, 21-31**

1150 Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing. **2018, 30, 141-154** 7

1149 T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. **2018, 46, 131-146** 10

1148 Optimized DNA electroporation for primary human T cell engineering. **2018, 18, 4** 32

1147 Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. **2018, 11, 22** 122

1146 Targeting Neoantigens for Personalised Immunotherapy. **2018, 32, 99-109** 7

1145 Constitutive and TNF β inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. **2018, 10,** 67

1144 IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. **2018, 36, 346-351** 282

1143 Emerging Systemic Therapies for Colorectal Cancer. **2018, 31, 179-191** 13

1142	Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma. <i>Molecular Therapy</i> , 2018 , 26, 1482-1493	11.7	29
1141	A Rapamycin-Activated Caspase 9-Based Suicide Gene. <i>Molecular Therapy</i> , 2018 , 26, 1266-1276	11.7	33
1140	Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. 2018 , 6, 509-516		53
1139	Adoptiver Immuntransfer und CAR-T-Zellen bei malignen Erkrankungen. 2018 , 21, 158-165		
1138	FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. 2018 , 23, 943-947		464
1137	CAR-T cells: the long and winding road to solid tumors. 2018 , 9, 282		215
1136	Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy. 2018 , 29, 534-546		37
1135	Regulation of T cell proliferation with drug-responsive microRNA switches. 2018 , 46, 1541-1552		22
1134	Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells. <i>Molecular Therapy</i> , 2018 , 26, 996-1007	11.7	8
1133	Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. 2018 , 22, 501-513.e7		78
1132	Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. 2018 , 10, 221-234		4
1131	Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach. 2018 , 67, 513-523		7
1130	Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression. 2018 , 9, 468		18
1129	Mechanogenetics for the remote and noninvasive control of cancer immunotherapy. 2018 , 115, 992-997		111
1128	Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells. 2018 , 66, 283-288		2
1127	Cell-Based Therapies for Canine Cancer. 2018 , 252-267		
1126	Immunotherapy with Genetically Modified T Cells. 2018 , 101-114		
1125	Synthetic Biology: Immunotherapy by Design. 2018 , 20, 95-118		21

1124	Glycan-directed CAR-T cells. 2018 , 28, 656-669	49
1123	Immunologic Approaches to Breast Cancer Therapy. 2018 , 924-933.e4	
1122	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. 2018 , 231-246	
1121	Toward Engineered Cells as Transformational and Broadly Available Medicines for the Treatment of Cancer. 2018 , 695-717	
1120	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens as Vaccine Targets for Cancer. 2018 , 10,	5
1119	Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy. 2018 , 29, 624-634	26
1118	From clinical proof-of-concept to commercialization of CAR T cells. 2018 , 23, 758-762	9
1117	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. 2018 , 18, 359-367	5
1116	Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. 2018 , 200, 459-468	109
1115	Hitting the Target: How T Cells Detect and Eliminate Tumors. 2018 , 200, 392-399	37
1114	CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction. 2018 , 6, 812-824	66
1113	Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. 2018 , 19, 745-754	19
1112	Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. 2018 , 6, 30	60
1111	Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety. 2018 , 31, 117-125	2
1110	Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. 2018 , 173, 1426-1438.e11	297
1109	Immunotherapy and Prevention of Pancreatic Cancer. 2018 , 4, 418-428	146
1108	Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. 2018 , 6, 605-616	143
1107	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. 2018 , 155, 29-32	209

1106	Synthetic Biology in Immunotherapy and Stem Cell Therapy Engineering. 2018 , 349-372	0
1105	Applications of Gene Editing Technologies to Cellular Therapies. 2018 , 24, 1537-1545	2
1104	Toxicities associated with immunotherapies for hematologic malignancies. 2018 , 31, 158-165	11
1103	Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. 2018 , 9, 1081	46
1102	CARs and other T cell therapies for MM: The clinical experience. 2018 , 31, 147-157	17
1101	Engineering a Dual Small Molecule Gated ZAP70 Switch in T Cells. 2018 , 7, 969-977	8
1100	Driving CARs on the uneven road of antigen heterogeneity in solid tumors. 2018 , 51, 103-110	49
1099	CAR T cell immunotherapy for human cancer. 2018 , 359, 1361-1365	1163
1098	Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. 2018 , 46, 391-401	17
1097	Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment. 2018 , 9, 516-526	35
1096	Rationale for immunological approaches to breast cancer therapy. 2018 , 37, 187-195	14
1095	Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. 2018 , 9, 838-847	108
1094	Modified T-cells (using TCR and CTAs), chimeric antigen receptor (CAR) and other molecular tools in recent gene therapy. 2018 , 19, 153-157	1
1093	Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain. 2018 , 24, 95-105	139
1092	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. 2018 , 38, 325-376	29
1091	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. 2018 , 7, e1380764	74
1090	Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses. 2018 , 1650-1668.e10	0
1089	Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. 2018 , 15, 47-62	1082

1088	Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. 2018 , 39, 167-176	93
1087	Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses. 2018 , 18, 1700187	39
1086	Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. 2018 , 13, 16-26	50
1085	Evolving Immunotherapy Approaches for Hepatocellular Carcinoma. 2018 , 93-110	
1084	Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. 2018 ,	0
1083	Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer. 2018 , 41, 130-140	24
1082	Cell-based immunotherapy in gynecologic malignancies. 2018 , 30, 23-30	7
1081	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. 2018 , 23-39	5
1080	New developments in immunotherapy for pediatric solid tumors. 2018 , 30, 30-39	11
1079	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. 2018 , 215, 141-157	118
1078	Anticancer cellular immunotherapies derived from umbilical cord blood. 2018 , 18, 121-134	13
1077	Early Phase Cancer Immunotherapy. 2018 ,	1
1076	Cellular Therapy. 2018 , 133-184	
1075	CAR T-Cell Therapies in Glioblastoma: A First Look. 2018 , 24, 535-540	80
1074	Chimeric antigen receptor transduced T cells: Tuning up for the next generation. 2018 , 142, 1738-1747	31
1073	Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development. 2018 , 59, 276-285	2
1072	T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. 2018 , 36, 2267-2280	375
1071	Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. 2018 , 38, 592-603	6

1070 . 2018,

1069 Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer. **2018**, 10, e3486 41068 CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients. **2018**, 35, 217-228 51067 Gestion des toxicités des lymphocytes T exprimant un récepteur d'antigène chimérique (CAR-T cells). **2018**, 105 Suppl 2, S188-S1971066 Développement des CAR-T dans les tumeurs solides. **2018**, 105 Suppl 2, S178-S187 01065 Biologie, concepts et principes des CAR-T cells. **2018**, 105 Suppl 2, S135-S146 01064 . **2018**, 71063 Making CAR T Cells a Solid Option for Solid Tumors. **2018**, 9, 2593 1001062 Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety. **2018**, 19, 201061 Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. **2018**, 61, 1320-1332 91060 Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research. **2018**, 59, 247-262 311059 CAR T Cell Therapy for Neuroblastoma. **2018**, 9, 2380 551058 CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. **2018**, 9, 2460 711057 Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors. **2019**, 12, 193-204 141056 Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?. **2018**, 8, 5784-5800 291055 Treating osteosarcoma with CAR T cells. **2019**, 89, e12741 141054 CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. **2018**, 12, 3885-3898 501053 CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. **2018**, 9, 2740 45

1052	CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors. 2018 , 8, 453	56
1051	p95HER2-T cell bispecific antibody for breast cancer treatment. 2018 , 10,	40
1050	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. 2018 , 175, 313-326	548
1049	Nanotechnology in Generation and Biomedical Application of Induced Pluripotent Stem Cells. 2018 , 08, 1841002	0
1048	The Potential of CAR T Cell Therapy in Pancreatic Cancer. 2018 , 9, 2166	63
1047	Cytokine release syndrome. 2018 , 4, 134-141	9
1046	Chimeric antigen receptor modified T-cells for cancer treatment. 2018 , 4, 225-243	7
1045	Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. 2018 , 115, E10702-E10711	35
1044	Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. 2018 , 9, 2486	109
1043	An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. 2018 , 13, e0205491	35
1042	Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. 2018 , 10,	60
1041	Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. 2018 , 2018, 4263520	51
1040	The biological basis and clinical symptoms of CAR-T therapy-associated toxicities. 2018 , 9, 897	59
1039	Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics. 2018 , 115, 1116-1129	19
1038	Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. 2018 , 8, 81	25
1037	Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells. 2018 , 38, 5049-5056	50
1036	Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell. 2018 , 6, 1314-1326	19
1035	Immunological-based approaches for cancer therapy. 2018 , 73, e429s	7

1034	Strategies to Address Chimeric Antigen Receptor Tonic Signaling. 2018 , 17, 1795-1815	80
1033	Landscape of Manufacturing Process of ATMP Cell Therapy Products for Unmet Clinical Needs. 2018 ,	3
1032	Identifying neoantigens for use in immunotherapy. 2018 , 29, 714-730	17
1031	From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells and. 2018 , 9, 25597-25616	38
1030	Chimeric antigen receptor-engineered T-cell therapy for liver cancer. 2018 , 17, 301-309	43
1029	Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells. 2018 , 12, 6563-6576	14
1028	[Immunotherapy - The New Era of Oncology]. 2018 , 97, S3-S47	
1027	Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. 2018 , 369, 1-10	22
1026	Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. 2018 , 44, E13	17
1025	DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. 2018 , 9, 1915	14
1024	Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. 2018 , 2018, 6240467	9
1023	Pediatric Cancer Immunotherapy: Opportunities and Challenges. 2018 , 20, 395-408	53
1022	Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy. 2018 , 29, 1017-1021.e1	14
1021	The Precision of the Rare Diseases. 2018 , 153-180	
1020	Chimeric Antigen Receptor Therapy. 2018 , 379, 64-73	880
1019	Cytokine release syndrome. 2018 , 6, 56	665
1018	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. 2018 , 19,	32
1017	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. 2018 , 9, 1740	108

1016	Beyond the Role of CD55 as a Complement Component. 2018 , 18, e11		29
1015	CAR T cells for infection, autoimmunity and allotransplantation. 2018 , 18, 605-616		101
1014	Adoptive Cell Therapy in Treating Pediatric Solid Tumors. 2018 , 20, 73		10
1013	Current Status of Gene Engineering Cell Therapeutics. 2018 , 9, 153		29
1012	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. 2018 , 9, 239		26
1011	Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. 2018 , 9, 1104		61
1010	Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy. 2018 , 9, 1409		42
1009	Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. 2018 , 13, e0199414		20
1008	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. <i>Molecular Therapy</i> , 2018 , 26, 1906-1920	11.7	23
1007	Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. 2018 , 36, 707-716		283
1006	Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors. 2018 , 16, 2063-2070		19
1005	New Immunotherapies in Oncology Treatment and Their Side Effect Profiles. 2018 , 31, 620-627		5
1004	Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. 2018 , 29, 739-756		22
1003	CAR T-cell Therapy: A New Era in Cancer Immunotherapy. 2018 , 19, 5-18		191
1002	Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy. 2018 , 24, 78-83		6
1001	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. 2018 , 20, 696-704		23
1000	Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice. 2018 , 35, 84		5
999	CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. 2018 , 11, 7		83

998	Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. 2018 , 11, 60	49
997	Cancer stem cells: Regulation programs, immunological properties and immunotherapy. 2018 , 52, 94-106	61
996	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. 2018 , 18, 653-664	17
995	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. 2018 , 24, 6185-6194	106
994	Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. 2018 , 11, 102	36
993	Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. 2018 , 9, 1717	32
992	Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018 , 50, 1-9	68
991	Engineering Platforms for T Cell Modulation. 2018 , 341, 277-362	8
990	Tumor Antigen Escape from CAR T-cell Therapy. 2018 , 8, 1219-1226	346
989	Driving cars to the clinic for solid tumors. 2018 , 25, 165-175	41
988	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. 2018 , 8, 972-987	66
987	Adoptive Cell Therapy for Melanoma. 2018 , 549-565	0
986	Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. 2018 , 13, e0197694	14
985	Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?. 2018 , 9, 135-148	38
984	TRUCKs with IL-18 payload: Toward shaping the immune landscape for a more efficacious CAR T-cell therapy of solid cancer. 2018 , 1, e7	10
983	Cancer immunotherapy: broadening the scope of targetable tumours. 2018 , 8,	67
982	Programming CAR-T cells to kill cancer. 2018 , 2, 377-391	138
981	Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. 2018 , 13, e0197349	41

980	Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer. 2018 , 12, 298-308		18
979	Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. 2019 , 68, 1052-1064		73
978	Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. 2019 , 30, 168-178		34
977	Melanoma Immunology and Immunotherapy. 2019 , 651-665		
976	Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. 2019 , 68, 1401-1415		12
975	Development of adaptive immune effector therapies in solid tumors. 2019 , 30, 1740-1750		23
974	T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. 2019 , 8, e1621676		11
973	Immunotherapeutic Approaches for the Treatment of Colorectal Cancer. 2019 , 84, 720-728		10
972	Single-Use Bioreactors for Manufacturing of Immune Cell Therapeutics. 2019 , 327-334		3
971	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. 2019 , 18, 125		113
970	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. <i>Molecular Therapy</i> , 2019 , 27, 1919-1929	11.7	101
969	Emerging trends in immunotherapy for pediatric sarcomas. 2019 , 12, 78		32
968	Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. 2019 , 56, 393-419		27
967	Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. 2019 , 11, 851-857		34
966	Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer. 2019 , 2019, 8103142		14
965	Leukemia Stem Cells in Hematologic Malignancies. 2019 ,		1
964	Application of CAR T cells for the treatment of solid tumors. 2019 , 164, 293-327		7
963	CAR T cells for brain tumors: Lessons learned and road ahead. 2019 , 290, 60-84		86

962	Immunobiology of chimeric antigen receptor T cells and novel designs. 2019 , 290, 100-113	9
961	Synergistic combination of oncolytic virotherapy with CAR T-cell therapy. 2019 , 164, 217-292	9
960	Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. 2019 , 33, 515-537	31
959	NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices. 2019 , 10, 2839	75
958	Lack of B and T cell reactivity towards IDH1 in blood and tumor tissue from LGG patients. 2019 , 144, 79-87	9
957	Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects. 2019 , 10, 764-769	37
956	Immunomodulatory Methods. 2019 , 297-334	2
955	Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy. 2019 , 8, 1744-1754	11
954	Immunotherapy Toxicities. 2019 , 28, 387-401	7
953	Adoptive T-Cell Therapy for Solid Malignancies. 2019 , 28, 465-479	6
952	Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. 2019 , 294, 18465-18474	17
951	Challenges and Opportunities for Childhood Cancer Drug Development. 2019 , 71, 671-697	8
950	Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing. 2019 , 30, 1477-1493	12
949	An AND-Gated Drug and Photoactivatable Cre- System for Spatiotemporal Control in Cell-Based Therapeutics. 2019 , 8, 2359-2371	11
948	Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. 2019 , 7, 1813-1823	37
947	. 2019 ,	8
946	Immunotherapy for pediatric brain tumors: past and present. 2019 , 21, 1226-1238	14
945	Imaging of T-cells and their responses during anti-cancer immunotherapy. 2019 , 9, 7924-7947	50

944	If we build it they will come: targeting the immune response to breast cancer. 2019 , 5, 37	76
943	Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. 2019 ,	
942	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. 2019 , 36, 471-482	139
941	Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer. 2019 , 12, 8015-8022	20
940	Application Of Adoptive Immunotherapy In Ovarian Cancer. 2019 , 12, 7975-7991	3
939	Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. 2019 , 110, 3079-3088	20
938	NK-Cell-Encapsulated Porous Microspheres via Microfluidic Electrospray for Tumor Immunotherapy. 2019 , 11, 33716-33724	42
937	Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies. 2019 , 34, 1780-1788	7
936	The current state of immunotherapy for gliomas: an eye toward the future. 2019 , 131, 657-666	48
935	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. 2019 , 20,	24
934	Clinical lessons learned from the first leg of the CAR T cell journey. 2019 , 25, 1341-1355	200
933	Engineering χ cells limits tonic signaling associated with chimeric antigen receptors. 2019 , 12,	10
932	Genetically engineered T cells for cancer immunotherapy. 2019 , 4, 35	89
931	T cell engineering for adoptive T cell therapy: safety and receptor avidity. 2019 , 68, 1701-1712	18
930	Conventional CARs versus modular CARs. 2019 , 68, 1713-1719	19
929	Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. 2019 , 8,	23
928	Defining precision cellular immunotherapy: seeking biomarkers to predict and optimize outcomes of T cell therapies in cancer. 2019 , 2, 25-25	1
927	CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. 2019 , 10, 4355	127

926	Nebenwirkungen von CAR-T-Zellen. 2019 , 22, 41-46	0
925	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. 2019 , 10, 2310	15
924	Adoptive cell transfer therapy for hepatocellular carcinoma. 2019 , 13, 3-11	28
923	Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia. 2019 , 127-140	
922	Engineering and Design of Chimeric Antigen Receptors. 2019 , 12, 145-156	149
921	Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor. 2019 , 12, 16-25	5
920	Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. 2019 , 11, 335-345	28
919	The First Step in Adoptive Cell Immunotherapeutics: Assuring Cell Delivery via Glycoengineering. 2018 , 9, 3084	12
918	CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. 2019 , 10, 128	339
917	Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. 2019 , 7, 1345-1357	39
916	Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer. 2019 , 11,	11
915	Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. 2019 , 39, 34	29
914	Precision Medicine in Cancer Therapy. 2019 ,	1
913	Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy. 2019 , 472, 55-64	11
912	An Antibody Fab Fragment-based Chimeric Antigen Receptor Could Efficiently Eliminate Human Thyroid Cancer Cells. 2019 , 10, 1890-1895	4
911	Precision Medicine-Enabled Cancer Immunotherapy. 2019 , 178, 189-205	6
910	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. 2019 , 307, 108-138	26
909	Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. 2019 , 10, 2681	48

908	Target selection for CAR-T therapy. 2019 , 12, 62	64
907	Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?. 2019 , 104, 1302-1308	40
906	Towards Immunotherapy for Pediatric Brain Tumors. 2019 , 40, 748-761	43
905	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. 2019 , 84, 227-240	34
904	CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. 2019 , 37, 107411	8
903	The 100 top-cited studies in cancer immunotherapy. 2019 , 47, 2282-2292	16
902	Species and speciation. 2019 , 19-37	
901	The making and function of CAR cells. 2019 , 212, 53-69	11
900	The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. 2019 , 10, 2235	54
899	Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. 2019 , 116, 11978-11987	37
898	Immune cell therapy for hepatocellular carcinoma. 2019 , 12, 52	41
897	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. 2019 , 15, 619-636	46
896	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. 2019 , 8,	72
895	Novel biomanufacturing platform for large-scale and high-quality human T cells production. 2019 , 13, 34	10
894	Switching on the green light for chimeric antigen receptor T-cell therapy. 2019 , 8, e1046	9
893	An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. 2019 , 39, e70-e78	19
892	Current Status of Immunotherapies for Treating Pancreatic Cancer. 2019 , 21, 60	24
891	Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. 2019 , 12, 50	26

890	Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction. 2019 , 60, 879-881	10
889	CAR T-Cells Targeting the Integrin $\alpha 4 \beta 1$ and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. 2019 , 11,	72
888	CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. 2019 , 141, 41-46	16
887	Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel. 2019 , 11, 2393-2404	10
886	Speciation. 2019 , 145-171	
885	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. 2019 , 40, 511-523	94
884	Novel approaches to promote CAR T-cell function in solid tumors. 2019 , 19, 789-799	3
883	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. 2019 , 143, 63-144	26
882	T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. 2019 , 42, 1-10	5
881	The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy. <i>Molecular Therapy</i> , 2019 , 27, 747-756	11.7 38
880	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. 2019 , 20,	140
879	Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. 2019 , 35, 489-503.e8	123
878	Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. 2019 , 11, 621-631	22
877	Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. 2019 , 42, 607-616	20
876	Engineering advanced cancer therapies with synthetic biology. 2019 , 19, 187-195	28
875	Immunotherapy of gynecological cancers. 2019 , 60, 97-110	10
874	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer. 2019 , 9, 176	45
873	Targeting immune cells for cancer therapy. 2019 , 25, 101174	88

872	A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy. 2019 , 30, 413-428	21
871	Immunotherapy of pancreatic cancer. 2019 , 164, 189-216	23
870	Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. 2019 , 46, 15-24	57
869	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. 2019 , 25, 4014-4025	66
868	New Developments in Imaging Cell-Based Therapy. 2019 , 60, 730-735	12
867	Synthetic T cell receptor-based lymphocytes for cancer therapy. 2019 , 141, 47-54	10
866	Current Landscape of Immunotherapy in Breast Cancer: A Review. 2019 , 5, 1205-1214	143
865	Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. 2019 , 116, 7624-7631	123
864	Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. 2019 , 23, 447-456	5
863	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. 2019 , 12, 195-205	44
862	Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T'Cell Therapy for Solid Tumors. 2019 , 79, 401-415	13
861	Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. 2019 , 10, 263	39
860	Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. 2019 , 13, 57-68	18
859	A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. 2019 , 29, 307-319	10
858	A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer. 2019 , 25, 2925-2934	20
857	Bispecific Antibodies in the Treatment of Hematologic Malignancies. 2019 , 106, 781-791	33
856	Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). 2019 , 8,	55
855	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. 2019 , 35, 221-237.e8	157

854	Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. 2019 , 9, 56	21
853	T Cell-Redirecting Strategies to 'STAB' Tumors: Beyond CARs and Bispecific Antibodies. 2019 , 40, 243-257	15
852	The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescence. 2019 , 40, 289-302	2
851	Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. 2019 , 33, 98-110	66
850	Cell-Based Cancer Immunotherapy. 2019 , 1-12	
849	EGFR: An Oncogene with Ambiguous Role. 2019 , 2019, 1092587	15
848	Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway. 2019 , 10, 6037-6047	20
847	Targeting cancers through TCR-peptide/MHC interactions. 2019 , 12, 139	33
846	CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges. 2019 , 20,	15
845	Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. 2019 , 12, 128	52
844	NK Cell Metabolism and TGF β Implications for Immunotherapy. 2019 , 10, 2915	19
843	The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse Brain. 2019 , 30, 169-181	10
842	Current Progress in CAR-T Cell Therapy for Solid Tumors. 2019 , 15, 2548-2560	107
841	CAR T Cells: A Snapshot on the Growing Options to Design a CAR. 2019 , 3, e172	21
840	Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. 2019 , 42, 126-135	116
839	T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments. 2019 , 31, 430-438	6
838	Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model. 2019 , 42, 33-42	26
837	Anti-ER CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against ER-positive Ovarian Cancer. 2019 , 42, 284-296	22

836	Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians. 2019 , 129, 434-441	8
835	Redirecting T cells to treat solid pediatric cancers. 2019 , 38, 611-624	1
834	Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. 2019 , 111, 409-418	60
833	The Current Status of Immunotherapy in Thoracic Malignancies. 2019 , 45-75	
832	Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer. 2019 , 69, 2061-2075	26
831	Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. 2019 , 65, 519-529	3
830	Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. 2018 , 9, 3062	37
829	Influenza vaccine: Where are we and where do we go?. 2019 , 29, e2014	40
828	Entering the Modern Era of Gene Therapy. 2019 , 70, 273-288	188
827	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. 2019 , 25, 2042-2048	43
826	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. 2019 , 25, 358-368	41
825	Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies. 2019 , 33, 1039-1043	9
824	Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells. 2018 , 9, 3180	21
823	Enhancing tumor T cell infiltration to enable cancer immunotherapy. 2019 , 11, 201-213	62
822	T-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancer. 2019 , 141, 23-40	15
821	mRNA as novel technology for passive immunotherapy. 2019 , 76, 301-328	51
820	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. 2019 , 19, 29-42	8
819	Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective. 2019 , 234, 5827-5841	17

818	Signaling of the ErbB Receptor Family in Carcinogenesis and the Development of Targeted Therapies. 2019 , 231-242	
817	Emerging Cellular Therapies for Cancer. 2019 , 37, 145-171	175
816	Immunotherapy of Sarcoma. 2019 ,	
815	Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density. 2019 , 141, 251-261	27
814	Cell-based immunotherapy approaches for multiple myeloma. 2019 , 120, 38-44	24
813	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. 2019 , 25, e155-e162	28
812	MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. 2019 , 120, 5010-5017	19
811	Targeting PVR (CD155) and its receptors in anti-tumor therapy. 2019 , 16, 40-52	58
810	Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. 2019 , 141, 3-22	26
809	Checkpoints and beyond - Immunotherapy in colorectal cancer. 2019 , 55, 78-89	21
808	Steering CAR T cells to distinguish friend from foe. 2019 , 8, e1271857	13
807	Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice. 2020 , 19, 178-186	6
806	Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. 2020 , 205, 107419	43
805	Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. 2020 , 39, 469-485	46
804	Determinants of response and resistance to CAR T cell therapy. 2020 , 65, 80-90	28
803	CART manufacturing process and reasons for academy-pharma collaboration. 2020 , 217, 39-48	4
802	Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice. 2020 , 469, 162-172	4
801	Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging. 2020 , 15, e0223814	17

800	The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells. 2019 , 21,	14
799	Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. 2020 , 34, 127-145	15
798	An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. 2020 , 367, 446-453	126
797	Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma. 2020 , 123, 109685	26
796	Current challenges and emerging opportunities of CAR-T cell therapies. 2020 , 319, 246-261	34
795	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. 2020 , 17, 147-167	347
794	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. 2020 , 121, 109625	50
793	Important aspects of T-cell collection by apheresis for manufacturing chimeric antigen receptor T cells. 2020 , 3, e75	4
792	The therapeutic landscape for cells engineered with chimeric antigen receptors. 2020 , 38, 233-244	75
791	AAVS1 site-specific integration of the CAR gene into human primary T cells using a linear closed-ended AAV-based DNA vector. 2020 , 22, e3157	2
790	CAR-T-Zell-Therapie: Biologie, Wirkungen, Nebenwirkungen, Zulassung und Kosten. 2020 , 35, 47-51	
789	Challenges and Opportunities to Improve CAR T-Cell Therapy. 2020 , 63-80	1
788	B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. 2020 , 9, 1684127	17
787	Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas. 2020 , 137-163	1
786	CAR T-Cell Therapy for CNS Malignancies. 2020 , 165-198	
785	Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. 2020 , 8, 1485-1495	9
784	Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting. 2020 , 21,	11
783	Cancer Biology and Advances in Treatment. 2020 ,	0

782	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. 2020 , 10, 565857	7
781	Challenges and Opportunities for Pancreatic Cancer Immunotherapy. 2020 , 38, 788-802	81
780	Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. 2020 , 11, 215-228.e5	26
779	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. 2020 , 18, 587-601	14
778	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. <i>Molecular Therapy</i> , 2020 , 28, 2320-2339	74
777	Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. 2020 , 16, 1029-1042	3
776	Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer. 2020 , 131, 110562	7
775	Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells. 2020 , 19, 14-23	4
774	Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. 2020 , 9, e1191	13
773	Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. 2020 , 9, e1154	2
772	Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy. 2020 , 8,	5
771	A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. <i>Molecular Therapy</i> , 2020 , 28, 2564-2576	11.7 4
770	The Whole Body as the System in Systems Immunology. 2020 , 23, 101509	12
769	Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. 2020 , 22, 573-580	32
768	Immunotherapy for advanced hepatocellular carcinoma, where are we?. 2020 , 1874, 188441	22
767	Immune Literacy: Reading, Writing, and Editing Adaptive Immunity. 2020 , 23, 101519	8
766	CAR-T in solid tumors: Blazing a new trail through the brambles. 2020 , 260, 118300	6
765	Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. 2020 , 11, 1965	36

764	An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours. 2020 , 6, 308-319	6
763	CAR T cell therapy. 2021 , 44, 69-73	0
762	ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3 β Phosphorylation. 2020 , 23, 101023	9
761	Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity. 2020 , 9, e1147	4
760	Immunotherapies and Combination Strategies for Immuno-Oncology. 2020 , 21,	26
759	Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. 2020 , 8,	5
758	Engineering Next-Generation CAR-T Cells for Better Toxicity Management. 2020 , 21,	18
757	Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. 2020 , 21,	7
756	Clinical implication of cellular vaccine in glioma: current advances and future prospects. 2020 , 39, 257	11
755	Complications after CD19+ CAR T-Cell Therapy. 2020 , 12,	10
754	Adoptive T cell therapy: Boosting the immune system to fight cancer. 2020 , 49, 101437	11
753	Precise T cell recognition programs designed by transcriptionally linking multiple receptors. 2020 , 370, 1099-1104	40
752	Autologous non-human primate model for safety assessment of transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor. 2020 , 9, e1207	2
751	Cytokine Storm. 2020 , 383, 2255-2273	757
750	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. 2020 , 1, 100041	19
749	Recent Advances on Rare Earth Upconversion Nanomaterials for Combined Tumor Near-Infrared Photoimmunotherapy. 2020 , 8, 596658	3
748	Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. 2020 , 18, 428	27
747	[Strategies of tumor-specific targeting based on the antigenic tumor specificities and the tumor microenvironment characteristics]. 2020 , 36 Hors série n° 1, 56-60	

746	PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo. 2020 , 8, 57	5
745	Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. 2020 , 8, 56	5
744	Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. 2020 , 12,	3
743	Sepsis in Immunocompromised Patients Without Human Immunodeficiency Virus. 2020 , 222, S156-S165	6
742	Commentary: Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice. 2020 , 11, 1503	1
741	The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. 2020 , 12,	11
740	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. 2020 , 10, 1243	34
739	The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. 2020 , 12,	8
738	Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses. 2020 , 8,	1
737	A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors. 2020 , 21, 73	1
736	CAR-T design: Elements and their synergistic function. 2020 , 58, 102931	48
735	Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield. 2020 , 12,	8
734	Inflammatory Cells in Diffuse Large B Cell Lymphoma. 2020 , 9,	10
733	Thermal Control of Engineered T-cells. 2020 , 9, 1941-1950	13
732	Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. 2020 , 20, 394-408	7
731	CAR T cells: Living HIV drugs. 2020 , 30, 1-14	1
730	Brief Overview of Chimeric Antigen Receptor-Mediated Immunotherapy for Glioblastoma Multiforme. 2020 , 507-513	
729	Mechanogenetics for cellular engineering and cancer immunotherapy. 2020 , 66, 88-94	4

728	Current and emerging biologic therapies for triple negative breast cancer. 2020 , 1-12	5
727	Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors. 2020 , 83, 719-724	2
726	CAR T-cell therapy for triple-negative breast cancer: Where we are. 2020 , 491, 121-131	9
725	Developing a safe and effective CAR T-cell immunotherapy for breast cancer: progress and pitfalls. 2020 , BMT48	3
724	Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals. 2020 , 11, 573179	7
723	Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture. 2020 , 11, 565631	13
722	RNA-electroporated T cells for cancer immunotherapy. 2020 , 9, 1792625	2
721	Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine. 2020 , 10, 605633	11
720	[Perspectives on CAR T-cell treatment]. 2020 , 41, 149-154	1
719	CAR-T cell therapy for lung cancer: a promising but challenging future. 2020 , 12, 4516-4521	8
718	Immunogenic chemotherapy in two mouse colon cancer models. 2020 , 111, 3527-3539	5
717	Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. 2020 , 142, 18874-18885	7
716	Beyond CAR T cells: Engineered V β V α T cells to fight solid tumors. 2020 , 298, 117-133	3
715	Innovative approaches to immunotherapy in breast cancer. 2020 , 12, 4536-4540	1
714	The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. 2020 , 18, 134	13
713	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. 2020 , 11, 1973	48
712	Podoplanin as an Attractive Target of CAR T Cell Therapy. 2020 , 9,	3
711	Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. 2020 , 9, 1806009	9

710	CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19HLA-C1 Malignant B Cells While Sparing CD19HLA-C1 Healthy B Cells. 2020 , 12,	7
709	Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. 2020 , 5,	31
708	Engineering Immune Cells for Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies. 2020 , 11, 1792	8
707	The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview. 2020 , 12,	30
706	Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. 2020 , 11, 4166	21
705	Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. 2020 , 8,	2
704	The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. 2020 , 14, 603647	12
703	Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma. 2020 , 2, 469-480	2
702	Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. 2020 , 13, 168	51
701	Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells. 2020 , 21,	3
700	Considerations for setting occupational exposure limits for novel pharmaceutical modalities. 2020 , 118, 104813	2
699	B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors. 2020 , 17, 180-189	27
698	The update of chimeric antigen receptor-T cells therapy in glioblastoma. 2020 , 83, 442-445	0
697	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. 2020 , 51, 100702	32
696	Breast cancer: insights in disease and influence of drug methotrexate. 2020 , 11, 646-664	13
695	Current Advances in Osteosarcoma. 2020 ,	3
694	Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. 2020 , 12,	13
693	Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. 2020 , 9,	24

692	A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. 2020 , 17, 278-292	4
691	Cancer immunotherapy: dawn of the death of cancer?. 2020 , 1-18	1
690	PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer. 2020 , 20, 965-970	5
689	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. 2020 , 11, 888	22
688	SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy. 2020 , 92, e12917	2
687	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. 2020 , 11, 1128	17
686	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. 2020 , 11, 369	97
685	Clinical development of immunotherapies for HER2 breast cancer: a review of HER2-directed monoclonal antibodies and beyond. 2020 , 6, 10	56
684	Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth. 2020 , 17, 9-20	16
683	Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours. 2020 , 12,	19
682	T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. 2020 , 147, 281-295	20
681	Longitudinal imaging of T cell-based immunotherapy with multi-spectral, multi-scale optoacoustic tomography. 2020 , 10, 4903	4
680	Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review. 2020 , 11, 326	27
679	Immune-Based Approaches for the Treatment of Pediatric Malignancies. 2020 , 4, 353-370	2
678	Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology. 2020 , 4, 121-139	5
677	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. 2020 , 149, 102927	7
676	Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. 2020 , 142, 6554-6568	22
675	Immunotherapy: Newer Therapeutic Armamentarium against Cancer Stem Cells. 2020 , 2020, 3963561	6

674	Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. 2020 , 527, 350-357	14
673	Tumor Microenvironment. 2020 ,	6
672	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. 2020 , 17, 474-502	126
671	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. 2020 , 11, 482	30
670	Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis. 2020 , 16, 597-612	8
669	[Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer]. 2020 , 54, 3-16	6
668	Prospects and challenges for use of CAR T cell therapies in solid tumors. 2020 , 20, 503-516	16
667	Synthetic immunity by remote control. 2020 , 10, 3652-3667	12
666	Advanced diagnostic aids for oral cancer. 2020 , 66, 101034	6
665	Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab. 2020 , 13, 5515-5527	3
664	Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. 2020 , 108, 1067-1079	20
663	Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models. <i>Molecular Therapy</i> , 2020 , 28, 2271-2285	11.7 21
662	Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. 2020 , 9, 1785608	7
661	Augmenting engineered T-cell strategies in solid cancers through epigenetic priming. 2020 , 69, 2169-2178	3
660	Generation, ex vivo expansion and safety of engineered PD1-knockout primary T cells from cynomolgus macaques. 2020 , 124, 100-108	2
659	Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. 2020 , 9, 1777064	14
658	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. 2020 , 26, 1759-1769	5
657	Fasten the seat belt: Increasing safety of CAR T-cell therapy. 2020 , 29, 1039-1045	1

656	Galunisertib enhances chimeric antigen receptor-modified T cell function. 2020 , 64,	4
655	EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma. 2020 , 17, 1406-1414	6
654	Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-G CAR Expression and Inducible Cytokines. 2020 , 12,	32
653	A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts. 2020 , 21,	11
652	Engineering light-controllable CAR T cells for cancer immunotherapy. 2020 , 6, eaay9209	44
651	CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. 2020 , 2020, 1924379	26
650	Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. 2019 , 9, 1529	19
649	CAR T cells: continuation in a revolution of immunotherapy. 2020 , 21, e168-e178	86
648	Tumor antigens in glioma. 2020 , 47, 101385	19
647	The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction. 2020 , 69, 465-476	19
646	Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer. 2020 , 21,	8
645	Taming the T cell. 2020 , 68, 53-55	1
644	Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. 2020 , 5,	114
643	Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. 2020 , 9,	27
642	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. 2020 , 12,	17
641	Methods to edit T cells for cancer immunotherapy. 2020 , 631, 107-135	3
640	Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. 2020 , 20, 1578-1589	125
639	Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. 2020 , 12,	36

638	Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. 2020 , 21,	23
637	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. 2020 , 26, 270-280	97
636	Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors. 2020 , 26, 2444-2451	50
635	Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. 2020 , 47, 1-15	7
634	Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. 2020 , 11, 312	16
633	New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. 2020 , 98, 299-327	14
632	Biologic therapy for advanced breast cancer: recent advances and future directions. 2020 , 20, 1009-1024	11
631	Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth. 2020 , 9,	35
630	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. 2020 , 20, 469-480	5
629	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. 2020 , 26, 720-731	60
628	Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor positive rhabdomyosarcoma. 2020 , 126 Suppl 9, 2093-2100	9
627	T-cell-based breast cancer immunotherapy. 2021 , 72, 90-101	12
626	Cellular immunotherapies for cancer. 2021 , 190, 41-57	16
625	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. 2021 , 11, 1129-1147	15
624	Biomarkers for predicting the outcome of various cancer immunotherapies. 2021 , 157, 103161	5
623	Cardiotoxic mechanisms of cancer immunotherapy - A systematic review. 2021 , 323, 179-187	16
622	Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. 2021 , 72, 365-382	8
621	Nanotechnology-Based CAR-T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. 2021 , 31, 2004713	5

620	Sarcomas of Bone and Soft Tissues in Children and Adolescents. 2021,	0
619	T-cell-engaging Therapy for Solid Tumors. 2021, 27, 1595-1603	8
618	Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma. 2021, 21, 21-34	2
617	Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy - what are we doing; where are we going?. 2021, 21, 627-637	13
616	Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. 2021, 268, 120584	11
615	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. 2021, 157, 103167	12
614	Transforming nanobodies into high-precision tools for protein function analysis. 2021, 320, C195-C215	4
613	The emerging role of immunotherapy for the treatment of sarcoma. 2021, 123, 730-738	8
612	Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors. 2020, 10, 574860	5
611	CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy. 2021, 90, 107201	3
610	The toxicity of cell therapy: Mechanism, manifestations, and challenges. 2021, 41, 659-667	3
609	Engineering precision therapies: lessons and motivations from the clinic. 2021, 6, ysaa024	1
608	Emerging Immunotherapies in the Treatment of Brain Metastases. 2021, 26, 231-241	12
607	Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. <i>Molecular Therapy</i> , 2021, 29, 702-717	11.7 17
606	Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. 2021, 21, 145-160	5
605	CAR T cell therapies for patients with multiple myeloma. 2021, 18, 71-84	61
604	Synthetic promoters to induce immune-effectors into the tumor microenvironment. 2021, 4, 143	3
603	Chimeric Antigen Receptor beyond CAR-T Cells. 2021, 13,	6

602	Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. 2021 , 131,	13
601	T cell circuits that sense antigen density with an ultrasensitive threshold.	0
600	CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. 2021 , 12, 1804-1814	11
599	CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. 2021 , 27, 1538-1552	14
598	A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. 2021 , 10, e1291	3
597	mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells. 2021 , 21, 3748-3761	0
596	CAR T-Cell Therapy with NKG2D Chimeric Antigen Receptor in Relapsed/ Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. 2021 , 14, 138-148	
595	Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. 2021 , 10, 1945804	4
594	Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies. 2021 , 3, vdab027	7
593	Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. 2021 , 54, 44-58	3
592	CAR T cells in solid tumors: challenges and opportunities. 2021 , 12, 81	72
591	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. 2021 , 12, 511	23
590	Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. 2021 , 1330, 33-54	1
589	CAR-T Therapy, the End of a Chapter or the Beginning of a New One?. 2021 , 13,	2
588	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. 2021 , 13,	5
587	Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. 2021 , 70, 2503-2515	2
586	Clinically-driven design of synthetic gene regulatory programs in human cells.	6
585	Cellular therapy for the treatment of solid tumors. 2021 , 60, 103056	5

584	Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. 2021 , 112, 1417-1428	2
583	From antibodies to living drugs: Quo vadis cancer immunotherapy?. 2021 , 72, 85-99	0
582	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.	
581	CAR T Cells: A Novel Biological Drug Class. 2021 , 159-198	
580	Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. 2021 , 20, 846-858	1
579	APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells. 2021 , 13, 7199-7210	
578	Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer. 2021 , 22,	3
577	CRISPR Takes the Front Seat in CART-Cell Development. 2021 , 35, 113-124	6
576	Building Multi-Dimensional Induced Pluripotent Stem Cells-Based Model Platforms to Assess Cardiotoxicity in Cancer Therapies. 2021 , 12, 607364	6
575	High cytokine levels and cytokine storm in the novel coronavirus infection. 2021 , 38-47	
574	Engineering advanced logic and distributed computing in human CAR immune cells. 2021 , 12, 792	20
573	How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn. 2021 , 11,	4
572	Driving CAR T cells towards dermatologic oncology. 2021 , 19, 359-362	3
571	Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review). 2021 , 21, 340	2
570	Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. 2021 , 88, 1056-1064	5
569	Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. 2021 , 21, 83	4
568	Neurological Complications of Targeted Therapies and Immunotherapies for Cancer. 2021 , 23, 1	2
567	New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy. 2021 , 22,	1

566	Understanding and treating the inflammatory adverse events of cancer immunotherapy. 2021 , 184, 1575-1588	17
565	Adoptive Cellular Therapy for Solid Tumors. 2021 , 41, 57-65	0
564	Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. 2021 , 12, 200	9
563	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.	0
562	Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. 2021 , 13,	3
561	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. 2021 , 11, 610303	22
560	Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals. 2021 , 22,	2
559	T cell circuits that sense antigen density with an ultrasensitive threshold. 2021 , 371, 1166-1171	25
558	CAR T-Cell Production Using Nonviral Approaches. 2021 , 2021, 6644685	4
557	Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy. 2021 , 31, 2100088	21
556	mRNA in cancer immunotherapy: beyond a source of antigen. 2021 , 20, 48	16
555	CAR-T-Zellen auf dem Weg zur praktischen Anwendung in der dermatologischen Onkologie. 2021 , 19, 359-363	
554	Research advances in chimeric antigen receptor-modified T-cell therapy (Review). 2021 , 21, 484	1
553	Quantifying the limits of CAR T-cell delivery in mice and men. 2021 , 18, 20201013	3
552	Targeting loss of heterozygosity for cancer-specific immunotherapy. 2021 , 118,	14
551	CART cell imaging: Paving the way for success in CART cell therapy. 2021 , 20, 625-633	4
550	Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. 2021 , 12, 658753	13
549	Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. 2021 , 206, 1561-1568	8

548	Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. 2021 , 12, 217	7
547	How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?. 2021 , 27, 134-142	0
546	Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. 2021 , 12, 1453	7
545	Chimeric Antigen Receptor Design Today and Tomorrow. 2021 , 27, 92-97	3
544	Systemic adverse effects and toxicities associated with immunotherapy: A review. 2021 , 12, 150-163	7
543	CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. 2021 , 44, 495-523	7
542	Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model. 2021 , 12, 628906	7
541	T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. 2021 , 137, 2337-2346	9
540	Pharmacologic Control of CAR T Cells. 2021 , 22,	3
539	Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with Clinical Insight. 2021 , 21, 221-236	1
538	CAR-T cells and BiTEs in solid tumors: challenges and perspectives. 2021 , 14, 65	11
537	Industrializing engineered autologous T cells as medicines for solid tumours. 2021 , 20, 476-488	3
536	Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors. 2021 , 503, 69-74	3
535	CAR T cell therapy in solid tumors: a short review. 2021 , 14, 143-149	4
534	Reactions Related to CAR-T Cell Therapy. 2021 , 12, 663201	6
533	CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation. 2021 , 13,	2
532	Advances in Synthetic Biology and Biosafety Governance. 2021 , 9, 598087	4
531	Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. 2021 , 2, 100227	16

530	A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses. 2021 , 1	6
529	Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of CCL20 motif chemokine receptor 6. 2021 , 66, 803-812	6
528	SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. 2021 , 13,	32
527	CAR-T-Zellen: Neue Therapien, neue Nebenwirkungen. 2021 , 24, 20-23	
526	SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. 2021 , 13,	61
525	A narrative review of chimeric antigen receptor-T (CAR-T) cell therapy for lung cancer. 2021 , 9, 808	3
524	Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives. 2021 , 97, 218-230	3
523	Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?. 2021 , 24, 986-996	2
522	Design and modular assembly of synthetic intramembrane proteolysis receptors for custom gene regulation in therapeutic cells.	2
521	Mechanisms of Neoantigen-Targeted Induction of Pyroptosis and Ferroptosis: From Basic Research to Clinical Applications. 2021 , 11, 685377	2
520	Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma. 2021 , 17, 771-792	0
519	Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies. 2021 , 16, 1105-1117	2
518	Flagella confer anti-tumor immunological effect activating Flagellin/TLR5 signalling within tumor microenvironment. 2021 , 11, 3165-3177	5
517	CAR-T cells Targeting Thyroid-stimulating Hormone Receptor (TSHR) Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.	
516	Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. 2021 , 147, 3725-3734	8
515	Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. 2021 , 14, 73	20
514	CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. 2021 , 15, 662064	16
513	The antigen-binding moiety in the driver's seat of CARs. 2022 , 42, 306-342	3

512	Navigating CAR-T cells through the solid-tumour microenvironment. 2021 , 20, 531-550	50
511	Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?. 2021 , 70, 651-663	1
510	Cellular based treatment modalities for unresectable hepatocellular carcinoma. 2021 , 12, 290-308	1
509	JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment. 2021 , 12, 638639	1
508	A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue. 2021 , 11, 12921	
507	Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. 2021 , 33, 1205-1220.e5	22
506	Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?. 2021 , 27, 6083-6094	2
505	CAR T-Cell Therapy: An Update for Radiologists. 2021 , 217, 1461-1474	4
504	Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. 2021 , 64, 9577-9591	5
503	The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. 2021 , 10,	0
502	Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. 2021 , 24, 102619	8
501	Emerging nanomaterials for cancer immunotherapy. 2021 , 2, 208-231	1
500	Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme. 2021 , 10, 5019-5030	2
499	CAR-based cell therapy: evaluation with bibliometrics and patent analysis. 2021 , 1-9	
498	Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. 2021 , 6, 100102	7
497	Immersion in the search for effective cancer immunotherapies. 2021 , 27, 63	2
496	Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. 2021 , 173, 281-305	12
495	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. 2021 , 12, 693016	7

494	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. 2021 , 223, 107892	4
493	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. 2021 , 157, 48-59	3
492	Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. 2021 , 7, 1051-1059	8
491	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. 2021 , 13,	3
490	Doubling down with CAR-T cell cancer immunotherapy: a two-step recognition circuit enables discrimination between target antigen high and low cancer cells. 2021 , 6, 286	
489	Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. 2021 , 11, 1721-1739	10
488	Exploiting Single-Cell Tools in Gene and Cell Therapy. 2021 , 12, 702636	4
487	Near-Infrared-Light Remote-Controlled Activation of Cancer Immunotherapy Using Photothermal Conjugated Polymer Nanoparticles. 2021 , 33, e2102570	15
486	Modified Therapeutic Antibodies: Improving Efficacy. 2021 ,	1
485	HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. 2021 , 10,	0
484	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. 2021 , 11, 2748-2763	46
483	New CARs on and off the road: challenges and new developments in CAR-T cell therapy. 2021 , 59, 116-126	0
482	Engineering Antibody-Based Therapeutics: Progress and Opportunities. 317-351	1
481	Can preclinical drug development help to predict adverse events in clinical trials?. 2021 , 27, 257-257	2
480	A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy. <i>Molecular Therapy</i> , 2021 ,	11.7 1
479	Curcumin as an Adjuvant to Cancer Immunotherapy. 2021 , 11, 675923	3
478	Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. 2021 , 12, 465	12
477	The State of Immunotherapy in Hepatobiliary Cancers. 2021 , 10,	4

476	PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. 2021 , 12, 665970	3
475	Programming Novel Cancer Therapeutics: Design Principles for Chimeric Antigen Receptors. 2021 , 353-375	
474	Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond. 2021 , 59, 70-84	6
473	Engineering enhanced CAR T-cells for improved cancer therapy. 2021 , 2, 780-793	6
472	VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. 2021 , 9,	4
471	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. 2021 , 10,	10
470	Control of the activity of CAR-T cells within tumours via focused ultrasound. 2021 , 5, 1336-1347	21
469	Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1. 2021 , 2, 100362	3
468	Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. 2021 , 11, 144	4
467	Chimeric antigen receptor T-cell therapy for breast cancer. 2021 , 17, 2961-2979	
466	Imaging-guided fine tuning of CAR synapse dynamics and T cell triggering.	
465	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. 2021 , 27, 6222-6234	4
464	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. 2021 , 12, 5271	5
463	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. 2021 , 69, 471-486	4
462	Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. 2021 , 297, 101033	1
461	Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma. 2021 , 13,	1
460	Engineering Cell-Based Systems for Smart Cancer Therapy. 2100134	2
459	A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy. 2021 , 12, 707211	3

458	The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. 2021 , 10,	6
457	Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control. 2021 ,	0
456	Imaging CAR T-cell kinetics in solid tumors: Translational implications. 2021 , 22, 355-367	2
455	Implications of Antigen Selection on T Cell-Based Immunotherapy. 2021 , 14,	0
454	Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. 2021 , 125, 1239-1250	6
453	Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. 2021 , 13,	3
452	Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors. 2021 , 13,	1
451	ANO7: Insights into topology, function, and potential applications as a biomarker and immunotherapy target. 2021 , 72, 101546	0
450	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. 2021 , 100, 102288	1
449	Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. 2021 , 14, 101227	0
448	Generation of Tumor-activated T cells Using Electroporation. 2021 , 142, 107886	1
447	Engineering solutions to design CAR-T cells. 2022 , 1-31	
446	Synthetic receptors for logic gated T cell recognition and function. 2021 , 74, 9-17	1
445	Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T cell therapy for glioblastoma.	2
444	Glycans as Targets and Mediators of T-Cell Immunotherapy. 2021 , 508-518	
443	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. 2021 , 13,	14
442	Pomalidomide improves the function of CD133- or HER2-specific CAR T cells. 2021 , 45, 157-165	
441	Avidity-Based Selection of Tissue-Specific CAR-T Cells from a Combinatorial Cellular Library of CARs. 2021 , 8, 2003091	3

440	Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment. 2020 , 1292, 113-130	2
439	Adoptive Cell Therapy of Systemic Metastases Using erbB-2-Specific T Cells Redirected with a Chimeric Antibody-Based Receptor. 2014 , 107-122	1
438	Engineered cell-based therapies: a vanguard of design-driven medicine. 2014 , 844, 369-91	2
437	Melanoma Antigens Recognized by T Lymphocytes. 2012 , 187-205	2
436	Advances and Challenges of CAR T Cells in Clinical Trials. 2020 , 214, 93-128	7
435	CAR-T cell and Personalized Medicine. 2019 , 1168, 131-145	2
434	Involvement of Heparanase in Gastric Cancer Progression and Immunotherapy. 2020 , 1221, 351-363	2
433	CAR T Cell Therapy Progress and Challenges for Solid Tumors. 2020 , 180, 297-326	15
432	Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. 2020 , 1257, 109-131	2
431	HER2-Targeted Therapy in Osteosarcoma. 2020 , 1257, 55-66	2
430	Chimeric Antigen Receptor (CAR) Redirected T Cells. 2021 , 251-302	1
429	Genetically modified T-cell therapy for osteosarcoma. 2014 , 804, 323-40	14
428	Hereditary Colorectal Cancer: Immunotherapy Approaches. 2018 , 385-399	1
427	Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses. 2014 , 207-232	2
426	Immunotherapy for Osteosarcoma. 2016 , 31-41	2
425	Chimeric antigen receptor T-cell therapy for solid tumors. 2016 , 3, 16006	152
424	A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. 2020 , 38, 426-432	42
423	A Fast and Sensitive Luciferase-based Assay for Antibody Engineering and Design of Chimeric Antigen Receptors. 2020 , 10, 2318	3

422	Acoustogenetic Control of CAR T Cells via Focused Ultrasound.	2
421	Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors.	2
420	Engineering clinically-approved drug gated CAR circuits.	3
419	ERK activation in CAR T cells is amplified by CD28-mediated increase in CD3 ζ phosphorylation.	1
418	Deletion of PTPN22 improves effector and memory CD8+ T cell responses to tumors. 2019 , 5,	15
417	Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. 2019 , 4,	10
416	A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. 2020 , 5,	17
415	Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. 2015 , 125, 1815-26	28
414	Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. 2016 , 126, 4262-4272	162
413	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. 2016 , 126, 3363-76	306
412	Driving an improved CAR for cancer immunotherapy. 2016 , 126, 2795-8	10
411	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. 2017 , 127, 929-941	183
410	Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. 2012 , 2012, 143-51	26
409	Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. 2012 , 2012, 143-151	52
408	Harnessing the immune response to target tumors. 2017 , 6, 710	2
407	Recent advances in T-cell engineering for use in immunotherapy. 2016 , 5,	13
406	Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody. 2013 , 8, e75589	9
405	Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene. 2015 , 10, e0136817	11

404	Chicken scFvs with an Artificial Cysteine for Site-Directed Conjugation. 2016 , 11, e0146907	5
403	Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review. 2020 , 13, 227-232	2
402	Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens. 2016 , 7, 56584-56597	6
401	Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice. 2017 , 8, 9488-9499	14
400	Driving better and safer HER2-specific CARs for cancer therapy. 2017 , 8, 62730-62741	29
399	Effective antitumor peptide vaccines can induce severe autoimmune pathology. 2017 , 8, 70317-70331	9
398	Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. 2017 , 8, 66137-66153	25
397	Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. 2017 , 8, 108584-108603	29
396	Retargeting of UniCAR T cells with an synthesized target module directed against CD19 positive tumor cells. 2018 , 9, 7487-7500	29
395	Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. 2015 , 6, 28911-28	35
394	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. 2016 , 7, 34582-98	8
393	The dark side of immunotherapy: pancreatic cancer.. 2020 , 3, 491-520	6
392	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 Via Chimeric Antigen Receptor T Cells.	1
391	Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. 2017 , 18, 271-280	5
390	A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells. 2021 , 22, 502-513	9
389	Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. 2020 , 12, 1341-1357	2
388	CAR-T-Zell-Therapie: Aussichten und Risiken.	1
387	Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions.. 2019 , 17, 11	1

386	Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy. 2020 , 12,	14
385	Why Immunotherapy Fails in Multiple Myeloma. 2021 , 2, 1-42	1
384	Gastrointestinal cancer stem cells as targets for innovative immunotherapy. 2020 , 26, 1580-1593	4
383	[Research progress of the side effect and application prospects of CAR-T cells in the treatment of malignant tumors]. 2016 , 37, 169-73	1
382	ADOPTIVE CELL THERAPY: CURRENT ADVANCES. 2020 , 1, 43-59	3
381	CAR T-cell therapy for gastric cancer: Potential and perspective (Review). 2020 , 56, 889-899	2
380	Impact of the immune system and immunotherapy in colorectal cancer. 2015 , 6, 208-23	98
379	Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. 2016 , 4, 13	5
378	NK Cell-Based Immunotherapies in Cancer. 2020 , 20, e14	35
377	Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. 2015 , 7, 980-92	29
376	The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. 2014 , 33, 421-33	8
375	Coating Iron Oxide Nanoparticles with Chitosan for Targeted Delivery of Nanocurcumin. 2020 , 18,	4
374	Near-infrared photoactivatable control of Ca(2+) signaling and optogenetic immunomodulation. 2015 , 4,	139
373	Domain-swapped T cell receptors improve the safety of TCR gene therapy. 2016 , 5,	37
372	GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. 2020 , 9,	16
371	Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy. 2021 , 12, 6949-6963	3
370	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. 2021 , 6, 117-129	3
369	Critical care management of chimeric antigen receptor T-cell therapy recipients. 2021 ,	1

368	Enhanced anti-tumor responses of tumor antigen-specific TCR-T cells genetically engineered to produce IL-7 and CCL19. 2021 ,	0
367	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. 2021 , 101508	3
366	Engineering living therapeutics with synthetic biology. 2021 , 20, 941-960	17
365	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. 2021 , 6, 367	5
364	Central Nervous System Metastases. 2022 , 36, 161-188	2
363	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives. 2021 , 10,	0
362	Depletion of T cells Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B. 2021 , 12, 734246	2
361	Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. 2021 , 27, 6527-6550	3
360	The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. 2021 , 1-20	0
359	Protein engineering: a driving force toward synthetic immunology. 2021 ,	
358	Probiotic-guided CAR-T cells for universal solid tumor targeting.	1
357	The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. 2021 , 23, 266-276	6
356	The triumvirate of NF- κ B, inflammation and cytokine storm in COVID-19. 2021 , 101, 108255	9
355	Cell therapy fights leukaemia.	1
354	Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation. 2012 , 12, 273-85	1
353	Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies. 2014 , 149-182	
352	Engineering T Cells to Target Tumor Cells. 2014 , 71-101	
351	The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic. 2014 , 127-135	

- 350 Chimeric antigen receptors: On the road to realising their full potential. **2015**, 5, 86
- 349 Immunopharmacologic Approaches to Treat Cancer. **2016**, 397-425
- 348 Development of Cancer Vaccine and Targeted Immune Checkpoint Therapies. **2017**, 225-241
- 347 Adoptive Cell Therapy of Gastric Cancer. **2017**, 149-161
- 346 Computational model of chimeric antigen receptors explains site-specific phosphorylation kinetics.
- 345 Inducible gene switches with memory in human T cells for cellular immunotherapy.
- 344 Autotransplantation of T-lymphocytes as a tool for antigen-specific immunotherapy of oncological diseases. **2018**, 20, 95-104 1
- 343 Cellular Immunotherapy for Sarcomas. **2019**, 139-152
- 342 CAR-T Cell Immune Therapy: Engineering T Cells to Treat Cancer. **2019**, 101-115
- 341 Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies. **2019**, 1143, 217-229 1
- 340 Introduction to Melanoma Immunology. **2019**, 1-15
- 339 Melanoma Immunology and Immunotherapy. **2019**, 1-15
- 338 Novel Immunotherapies and Novel Combinations of Immunotherapy. **2019**, 1-22
- 337 CD8+ T Cell Biology in Cytokine Storm Syndromes. **2019**, 141-161
- 336 Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma. 1
- 335 The common neoantigens in colorectal cancer are predicted and validated to be presented or immunogenic. 0
- 334 III. Chimeric Antigen Receptor T-cell Immure Therapy. **2019**, 108, 1375-1383
- 333 Dominant role of the β chain in rejection of tumor cells bearing a specific alloantigen in TCR β transgenic mice and in experiments. **2019**, 10, 4808-4821 3

- 332 CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers. **2020**, 2086, 1-10 0
- 331 Regional Gene Therapy for Cancer. **2020**, 55-71
- 330 Gastrointestinal Toxicities of Immunotherapy. **2020**, 201-222
- 329 A functional screening platform for engineering chimeric antigen receptors with reduced on-target, off-tumour activation.
- 328 A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue.
- 327 Non-invasive cell-tracking methods for adoptive T cell therapies. **2021**, 1
- 326 Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers. **2021**, 11, 2448-2467 1
- 325 CAR T Cell Therapy's Potential for Pediatric Brain Tumors. **2021**, 13, 2
- 324 Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors. 1
- 323 Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. **2021**, 12, 782775 1
- 322 CAR-T Cell Clinical Trials Experience (Past, Present and Future). **2020**, 303-375
- 321 Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. **2021**, 3, 1-22 2
- 320 Criteria to make animal studies more relevant to treating human cancer. **2021**, 74, 25-31 0
- 319 Recent advances in functionalized upconversion nanoparticles for light-activated tumor therapy.. **2021**, 11, 35472-35488 2
- 318 Feasibility of real-time in vivo⁸⁹Zr-DFO-labeled CAR T-cell trafficking using PET imaging.
- 317 T Cell Receptor Engineered T Cell Therapy in Oncology. **2020**, 377-408
- 316 Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. **2020**, 1165-1186
- 315 The Immune Landscape in Women Cancers. **2020**, 180, 215-249 1

314	Immunopathology and Immunotherapy for Breast Cancer. 2020 , 541-555	0
313	Genome Engineering Tools in Immunotherapy. 2020 , 73-102	
312	Thermal Control of T-cell Immunotherapy.	
311	Generation of an NF κ B-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy. 2021 , 12, 751138	1
310	CAR-T cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer. 2021 ,	2
309	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. 2021 , 21, 1333-1353	4
308	De novodesigned receptor transmembrane domains enhance CAR-T cell cytotoxicity and attenuate cytokine release.	1
307	Immunotherapy for Pediatric Sarcomas. 2021 , 165-180	
306	Current Mesothelioma Treatment and Future Perspectives.	
305	T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice. 2021 , 199-218	
304	Hurdles in Cancer Immunotherapy. 2021 , 597-635	
303	Colorectal cancer immunotherapy. 2013 , 15, 301-8	46
302	Advances in chimeric antigen receptor immunotherapy for neuroblastoma. 2013 , 16, 287-94	22
301	Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. 2015 , 7, 1022-38	5
300	Engineering Chimeric Antigen Receptors. 2017 , 9, 6-14	4
299	Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells. 2016 , 17, 95-115	12
298	Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma. 2017 , 6, 22-25	9
297	Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. 2018 , 8, 106-119	18

296	Molecular Approaches to Safe and Controlled Engineered T-cell Therapy. 2018 , 10, 16-23	6
295	Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy. 2017 , 2, 100-113	1
294	Target selection of CAR T cell therapy in accordance with the TME for solid tumors. 2019 , 9, 228-241	22
293	The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. 2019 , 9, 1846-1856	27
292	CAR-armed cell therapy for gliomas. 2019 , 9, 2554-2566	2
291	Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade. 2020 , 10, 688-703	6
290	[Advances in immunotherapy of acute myeloid leukemia by using chimeric antigen receptor modified T cells]. 2016 , 37, 160-3	1
289	[Management of cytokine release syndrome during chimeric antigen receptor-modified T cell therapy]. 2017 , 38, 907-912	0
288	[Progress in clinical studies of chimeric antigen receptor engineered T cells for treatment of childhood cancer]. 2017 , 19, 1219-1224	1
287	Innovative strategies to advance CAR T cell therapy for solid tumors. 2020 , 10, 1979-1992	2
286	Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy. 2021 , 13, 156-167	4
285	Immunotherapy in non-small cell lung cancer: Update and new insights. 2021 , 7, 1-21	4
284	Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. 2021 , 9,	0
283	Immunopharmacogenomics: a hope in the treatment of carcinoma. 2022 , 327-346	
282	HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. 2021 , 12, 1109	1
281	BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved antitumor activity.	0
280	c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer. 2021 , 13,	1
279	Synthetic biology: at the crossroads of genetic engineering and human therapeutics-a Keystone Symposia report. 2021 ,	1

278	Associa� Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies. 2021 , 43 Suppl 2, S46-S53		
277	Genetically Modified Cellular Therapies for Malignant Gliomas. 2021 , 22,		1
276	CRISPR/Cas9-mediated TGF�II disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. 2021 , 19, 482		1
275	Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. 2021 , 22,		4
274	Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. <i>Molecular Therapy</i> , 2021 ,	11.7	3
273	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. 2021 , 22,		1
272	Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor. 2021 , 11, 772862		2
271	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. 2021 , 1342, 273-295		1
270	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial.. 2022 , 165, 1-9		1
269	Regional Delivery of CAR-T Effectively Controls Tumor Growth in Colorectal Liver Metastasis Model.. 2021 , 272, 37-50		0
268	[Perspectives for the evolution and use of CAR-T cells].. 2021 , 108, S18-S27		
267	[Mechanisms of resistance and escape to CAR-T cells].. 2021 , 108, S128-S140		
266	Safety Switches Used for Cellular Therapies. 2022 , 91-107		
265	Synthetic mRNA for ex vivo therapeutic applications.. 2022 , 44, 100447		0
264	CAR-Ts: New Perspectives in Cancer Therapy.. 2022 ,		3
263	Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review.. 2022 , 27, 210-219		0
262	Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors.. 2022 , 10,		2
261	Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.. 2022 , 11,		0

260	A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine.. 2021 , 12, 788211	0
259	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance.. 2022 , 11,	1
258	The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer. 2022 , 55, 39-47	3
257	Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.. 2022 ,	
256	Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers.. 2022 , 14,	2
255	CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.. 2022 ,	2
254	Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity.. 2022 ,	1
253	The next wave of cellular immunotherapies in pancreatic cancer.. 2022 , 24, 561-576	4
252	iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.. 2022 , 13, 841107	4
251	In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery.. 2022 ,	0
250	Engineering CAR T cells for enhanced efficacy and safety.. 2022 , 6, 011502	0
249	Strategies for manufacturing cell therapy products aligned with patient needs.. 2022 , 167, 203-226	0
248	Developments in Solid Tumours. 2022 , 105-108	
247	The classification of life. 2022 , 251-341	
246	Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T-cells Regresses Refractory Solid Tumors.. 2022 ,	0
245	Light-Controllable Binary Switch Activation of CAR T Cells.. 2022 ,	0
244	A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell-surface proteins on target cells.. 2022 , 49,	
243	Immunotherapy in Lung Cancer: Current Landscape and Future Directions.. 2022 , 13, 823618	2

242	Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.. 2022 , 41, 193	1
241	Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy.. 2022 , 23, 127-133	2
240	Better by design: What to expect from novel CAR-engineered cell therapies?. 2022 , 107917	1
239	Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. 2021 , 9, e002755	0
238	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.. 2022 , 113, 253-294	
237	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. 2022 , 20, 1721727X2210787	
236	Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer.. 2022 , 5, 73-83	0
235	CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.. 2022 , 18, 2609-2626	2
234	CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.. 2022 , 13, 817296	4
233	Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.	
232	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.. 2022 , 375, eabl5447	9
231	Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions.. 2022 , 13, 846346	2
230	Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy.. 2022 , 14,	1
229	When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies.. 2022 , 12, 837995	1
228	A novel TanCAR targeting IL13R α and EphA2 for enhanced glioblastoma therapy.. 2022 , 24, 729-741	1
227	Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. 2022 , 100035	0
226	A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.. 2022 , 13, 840956	3
225	Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.. 2022 ,	0

224	Targeting of neutrophil activation in the early phase of the disease for prevention of Coronavirus disease-19 severity.. 2022,	0
223	Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.. 2022,	3
222	CAR-T cell therapy for lung cancer: Potential and perspective.. 2022,	5
221	Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.. 2022,	0
220	Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.. 2022, 13, 841425	0
219	Photopharmacological modulation of native CRAC channels using azoboronate photoswitches.. 2022, 119, e2118160119	0
218	Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis.. 2022, 198, 114955	0
217	To go or not to go? Biological logic gating engineered T cells.. 2022, 10,	0
216	Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination.. 2022,	3
215	Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.. 2022,	1
214	Hurdles to breakthrough in CAR T cell therapy of solid tumors.. 2022, 13, 140	5
213	Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors.. 2022, 1877, 188701	1
212	COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches.. 2022, 107, 108655	0
211	A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9. 2022, 10, 16	3
210	Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.. 2021, 79, 14	3
209	Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing.. 2021, 11,	2
208	Sensitizing solid tumors to CAR-mediated cytotoxicity using synthetic antigens.	0
207	Fast off-rate CD229 chimeric antigen receptor T cells efficiently target multiple myeloma, spare T cells, and exhibit reduced trogocytosis.	0

206	High cytokine levels and cytokine storm in the novel coronavirus infection. 2021 , 47-57	
205	Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".. 2021 , 12, 799206	5
204	Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy.. 2021 , 11, 789078	0
203	Modular design of synthetic receptors for programmed gene regulation in cell therapies.. 2022 , 185, 1431-1443.e16	5
202	DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy.. 2022 ,	4
201	B7-H3 Specific CAR T cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.. 2022 ,	0
200	Next-Generation CAR T-cell Therapies.. 2022 , OF1-OF14	1
199	Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.. 2022 , 13, 2154	2
198	Development of CAR T Cell Therapy in Children-A Comprehensive Overview.. 2022 , 11,	1
197	The tricks for fighting against cancer using CAR NK cells: A review.. 2022 , 101817	0
196	Data_Sheet_1.PDF. 2020 ,	
195	DataSheet_1.pdf. 2021 ,	
194	Cytokine storm and stem cell activation in unveiling potential targets for diagnosis and therapy. 2022 , 59-70	
193	Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors. 2022 , 11, 31	0
192	High throughput screen for the improvement of inducible promoters for tumor microenvironment cues.. 2022 , 12, 7169	1
191	BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.. 2022 , 17, e0266980	2
190	Direct Cell Radiolabeling for Cell Tracking with PET and SPECT Imaging.. 2022 ,	6
189	Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.. 2022 ,	0

188	Therapeutic Options in Neuro-Oncology. 2022 , 23, 5351	1
187	Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. 2022 , 13,	3
186	De novo-designed transmembrane domains tune engineered receptor functions.. 2022 , 11,	1
185	Chimeric antigen receptor (CAR) T cell therapy in hepatocellular carcinoma; a review of recent advances. 2021 , 4, 19-27	
184	CAR-T Cells and Other Related Technologies. 2022 , 281-314	
183	Immunotherapy for Colorectal Cancer.. 2022 ,	
182	T cells engineered to express immunoreceptors targeting the frequently expressed medullary thyroid cancer antigens calcitonin, CEA and RET M918T.. 2022 ,	1
181	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.. 2022 , 10,	3
180	CAR-T cells for cancer immunotherapy: the barriers ahead and the paths through. 1-15	1
179	Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy.	
178	Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. 2022 , 20,	0
177	Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. 13,	1
176	CAR-T Therapy in Clinical Practice: Technical Advances and Current Challenges. 2101262	
175	Next Generation Natural Killer Cells for Cancer Immunotherapy. 2022 , 13,	0
174	Emerging Therapies for Hepatocellular Carcinoma (HCC). 2022 , 14, 2798	8
173	CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells. 2022 , 13,	2
172	Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety. 10,	
171	Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo. 2022 , 12,	

170	Synthetic immunotherapy: programming immune cells with novel and sophisticated logic capabilities. 2022,	0
169	Overcome tumor relapse in CAR T cell therapy.	1
168	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. 10,	4
167	Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. 2022,	2
166	Induction of a Cytokine Storm Involves Suppression of the Osteopontin-Dependent TH1 Response.	1
165	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. 13,	1
164	A TCR-like CAR promotes sensitive antigen recognition and controlled T cell expansion upon mRNA vaccination.	
163	Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. 2022, 23, 7046	2
162	Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.	
161	Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. 10,	1
160	From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. Volume 15, 4061-4085	
159	A Mathematical Model for On-Target Off-Tumor Effect of CAR-T Cells on Gliomas. 2,	
158	The Dual Role of Innate Immune Response in Acetaminophen-Induced Liver Injury. 2022, 11, 1057	0
157	Antibody variable region engineering for improving cancer immunotherapy.	0
156	Cell Squeeze : Driving more effective CD8 T cell activation through cytosolic antigen delivery. 2022, 100091	0
155	Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot.	3
154	Neoantigens and NK Cells: Trick or Treat the Cancers?. 13,	1
153	Targeting Glycans for CAR Therapy: the Advent of Sweet CARs. <i>Molecular Therapy,</i> 2022,	11.7 0

152	EBAG9-silencing exerts an immune checkpoint function without aggravating adverse effects. <i>Molecular Therapy</i> , 2022 ,	11.7	1
151	Advances and challenges of CAR T therapy and suitability of animal models (Review). 2022 , 17,		0
150	Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors. 1-11		1
149	Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. OF1-OF12		0
148	Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. 13,		
147	CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. 13,		1
146	Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma. 2022 ,		7
145	Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. 3,		1
144	The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. 13,		
143	Nonviral mCDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. 2022 , 22,		
142	Current State of Cell Therapies for Gastrointestinal Cancers. 2022 , 28, 310-321		
141	Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma. <i>jnumed</i> .122.264284		
140	Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. 2022 , 3, 538-564		0
139	Current progress in CAR-T cell therapy for tumor treatment (Review). 2022 , 24,		1
138	Secretory co-factors in next-generation cellular therapies for cancer. 13,		
137	Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. 1-24		1
136	Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans. 13,		1
135	Safety switch optimization enhances antibody-mediated elimination of CAR T cells.		

- 134 CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues. 13,
- 133 Rapid generation of a mouse model for evaluating on-target normal tissue toxicity of human CAR-T cells using replication-defective recombinant adenovirus. **2022**,
- 132 Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects. 0
- 131 CAR-T Therapy: A Promising Cancer Treatment. 8, 100-110
- 130 Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. **2022**, 10, e004854 0
- 129 Applying a clinical lens to animal models of CAR-T cell therapies. **2022**, 27, 17-31 0
- 128 Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. **2022**, 14, 175883592211180
- 127 Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies. **2022**, 21, 153303382211184 0
- 126 Mathematical Modeling on Immunotherapy and Its Application for Deriving Cancer Therapy. **2022**, 1-33 0
- 125 Early Pathogenesis in Rabbit Hemorrhagic Disease Virus 2. 0
- 124 Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. **2022**, 14, 4192 0
- 123 Combinatorial suicide gene strategies for the safety of cell therapies. 13, 0
- 122 Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. **2022**, 7, 5
- 121 Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. 13, 0
- 120 Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. **2022**, 10, 2216 1
- 119 Rethinking cancer targeting strategies in the era of smart cell therapeutics. 1
- 118 High-performance multiplex drug-gated CAR circuits. **2022**, 1
- 117 Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors. 0

116	Chimeric antigen receptor engineered cells and their clinical application in infectious disease. 2022 , 2,	0
115	Current Progress of CAR-NK Therapy in Cancer Treatment. 2022 , 14, 4318	0
114	Treatment with anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion dogs.	0
113	Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes. 1-19	1
112	Development of Multiplexed Bead-Based Immunoassays for Profiling Soluble Cytokines and CD163 Using Mass Cytometry.	1
111	CAR-T therapy in Acute lymphocytic leukemia. 14, 305-310	0
110	Advances in the Pharmacological Activities and Effects of Perilla Ketone and Isoegomaketone. 2022 , 2022, 1-10	1
109	H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+patients with diffuse midline glioma. 2022 , 10, e005535	0
108	T Cell Immunotherapy of Cancer. 1-13	0
107	Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform. 2022 , 14, 4859	0
106	Novel technologies for improving the safety and efficacy of CAR-T cell therapy.	0
105	Chimeric antigen receptor T cells applied to solid tumors. 13,	0
104	Tumor buster - where will the CAR-T cell therapy missile go?. 2022 , 21,	1
103	Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells. 2022 , 14, 4854	0
102	Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. 2022 , 14, 5108	3
101	Clinical and Translational Advances in Glioma Immunotherapy.	1
100	Emerging frontiers in immuno- and gene therapy for cancer. 2022 ,	2
99	Safety switch optimization enhances antibody-mediated elimination of CAR T cells. 2,	0

- 98 The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better. 13, 0
- 97 Cellular Immunotherapy for Medulloblastoma. 0
- 96 Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells. **2022**, 14, 5033 1
- 95 Les cellules CAR-T : nouvelle perspective thérapeutique dans le traitement des tumeurs solides ?. **2022**, 14, 2S42-2S45 0
- 94 Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy. 0
- 93 Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe. **2022**, 14, 5351 0
- 92 Generation of induced pluripotent stem cell (iPSC) from NY-ESO-1-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs : The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology. 0
- 91 AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. **2022**, 11, 0
- 90 Toxicities following CAR-T therapy for hematological malignancies. **2022**, 111, 102479 0
- 89 Cytokine Release Syndrome and Sepsis. **2022**, 36, 735-748 0
- 88 Early pathogenesis in rabbit hemorrhagic disease virus 2. **2022**, 173, 105814 0
- 87 CAR T Cell Immunotherapy That Revolutionary Breakthrough in Human Oncology Treatment: A Review. **2022**, 13, 483-515 0
- 86 Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. **2022**, 23, 13696 0
- 85 Rapacaspase-9-based Suicide Gene Applied to the Safety of Il-1rap Car-t Cells. 0
- 84 CAR T-cells for colorectal cancer immunotherapy: Ready to go?. 13, 0
- 83 Recent progress of gene circuit designs in immune cell therapies. **2022**, 13, 864-873 0
- 82 Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism?. 13, 0
- 81 Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). **2022**, 23, 14255 0

80	Engineered T cell therapy for viral and non-viral epithelial cancers. 2022,	1
79	Mesenchymal stromal cells and alpha-1 antitrypsin have a strong synergy in modulating inflammation.	0
78	Immunotherapy. 2022, 309-328	0
77	The future of engineered immune cell therapies. 2022, 378, 853-858	2
76	Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. 2023, 20, 49-62	1
75	Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates. 2022, 14, 5674	0
74	Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours. 2022,	0
73	Multidimensional control of therapeutic human cell function with synthetic gene circuits. 2022, 378, 1227-1234	4
72	Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.	0
71	Engineering chimeric antigen receptor T cells for solid tumour therapy. 2022, 12,	0
70	RNA therapeutics for improving CAR T cell safety and efficacy.	0
69	Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. 2022, 14, 5983	0
68	Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes. 2022, 56, 409-419	0
67	Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. 13,	0
66	CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer.	0
65	Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point. 2022, 25, 105665	0
64	Improving Osteosarcoma Treatment: Comparative Oncology in Action. 2022, 12, 2099	0
63	Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. 2023, 9,	0

- 62 A Multiscale Protein Abundance Structured Population Kinetic Model Systematically Explores the Design Space of Constitutive and Inducible CAR-T cells. ○
- 61 Adoptive Cell Transfer for Solid Tumors. **2023**, ○
- 60 A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer. **2023**, 12, 248 ○
- 59 Biological Markers to Predict Outcome in Mechanically Ventilated Patients with Severe COVID-19 Living at High Altitude. **2023**, 12, 644 ○
- 58 A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy. **2023**, 21, ○
- 57 Is Nuclear Factor Erythroid 2-Related Factor 2 a Target for the Intervention of Cytokine Storms?. **2023**, 12, 172 1
- 56 PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105. **2023**, 9, e12688 ○
- 55 Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies. ○
- 54 Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future. **2022**, ○
- 53 Tumor-infiltrating lymphocytes: Prognostic considerations and current trials as adoptive cell therapy. **2023**, 403-426 ○
- 52 Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. 2206912 ○
- 51 Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. OF1-OF15 ○
- 50 Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. **2023**, 7, e0022-e0022 ○
- 49 CAR T cells: engineered immune cells to treat brain cancers and beyond. **2023**, 22, ○
- 48 CAR T-cell behavior and function revealed by real-time imaging. ○
- 47 Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march. **2023**, 97-131 ○
- 46 Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. **2023**, 3, 37-56 ○
- 45 Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. **2023**, 15, 648 ○

44	CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. 2023 , 22,	1
43	CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy. 2023 , 24, 2342	0
42	Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy. 2023 , 24, 2152	0
41	Research Status of CAR-T Cell Immunotherapy in Tumor Treatment. 2023 , 11, 24-36	0
40	Metabolic Challenges in Anticancer CD8 T Cell Functions. 2023 , 23,	1
39	Immunotherapy: Targeting Cancer Cells. 2023 , 179-217	0
38	mRNA-Based Therapeutics in Cancer Treatment. 2023 , 15, 622	0
37	Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model.	0
36	CAR T-cells to treat brain tumors. 2023 , 196, 76-98	0
35	Inhibition of mouse colon cancer growth following immunotherapy with a fraction of hydatid cyst fluid. 2023 , 249, 108501	0
34	Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. 2023 , 162, 114648	0
33	Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy. 2023 ,	0
32	Immunotherapies against HER2-Positive Breast Cancer. 2023 , 15, 1069	0
31	IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. 2023 , 11, e006239	0
30	Nanomodified Switch Induced Precise and Moderate Activation of CAR-T Cells for Solid Tumors. 2205044	0
29	CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens. 2023 , 12, 287	2
28	Optimizing the manufacturing and antitumour response of CAR T therapy. 2023 , 1, 271-285	0
27	Anti-ROR1 CAR-T cells: Architecture and performance. 10,	0

- 26 TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma. **2023**, 11, e006121 ○
- 25 Challenges of Anti-Mesothelin CAR-T-Cell Therapy. **2023**, 15, 1357 ○
- 24 CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. **2023**, 15, 1414 ○
- 23 Immunotherapy of Osteosarcoma. **2023**, 1-39 ○
- 22 Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain. **2023**, 16, ○
- 21 Engineering Circular Aptamer Assemblies with Tunable Selectivity to Cell Membrane Antigens In Vitro and In Vivo. **2023**, 15, 12822-12830 ○
- 20 CAR-T Therapies in Solid Tumors: Opportunities and Challenges. **2023**, 25, 479-489 1
- 19 Chimeric antigen receptor T cells therapy in solid tumors. ○
- 18 CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. **2023**, 13, 465 ○
- 17 The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. **2023**, 15, 1597 1
- 16 Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis. 14, ○
- 15 Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Solid Tumors. **2023**, ○
- 14 Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. **2023**, 21, ○
- 13 Immunotherapy for HER-2 positive breast cancer. 13, ○
- 12 The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. 14, ○
- 11 Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors. **2023**, 4, 1-16 ○
- 10 Remote control of cellular immunotherapy. ○
- 9 Emerging Targeted Therapies for HER2-Positive Breast Cancer. **2023**, 15, 1987 ○

- 8 Cell surface proteomics reveal a strategy for targeting myeloma through combinatorial targeting of TNFRSF8 and TMPRSS11E. ○
- 7 Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. **2023**, 14, ○
- 6 Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models. **2023**, 14, ○
- 5 A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor. ○
- 4 ST3GAL1 and β -spectrin pathways control CAR T cell migration to target tumors. ○
- 3 Immunotherapy in glioblastoma treatment: Current state and future prospects. 14, 138-159 ○
- 2 Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell Therapy. **2023**, 142, 104367 ○
- 1 Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. **2023**, 30, 5003-5023 ○